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CHAPTER 1 
INTRODUCTION 
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The oral route of drug administration is the most common and preferred 
method of delivery due to convenience and ease of ingestion. From a patient’s 
perspective, swallowing a dosage form is a comfortable and a familiar means of 
taking medication.
1, 2
 Although the oral route of administration is preferred, for 
many drugs it can be a problematic and inefficient mode of delivery for a number of 
reasons. Limited drug absorption resulting in poor bioavailability is paramount 
amongst the potential problems that can be encountered when delivering an active 
agent via the oral route.
3-5
 
Drug absorption from the gastrointestinal (GI) tract can be limited by a 
variety of factors with the most significant contributors being poor aqueous 
solubility and/or poor membrane permeability of the drug molecule. When 
delivering an active agent orally, it must first dissolve in gastric and/or intestinal 
fluids before it can then permeate the membranes of the GI tract to reach systemic 
circulation. Therefore, a drug with poor aqueous solubility will typically exhibit 
dissolution rate limited absorption, and a drug with poor membrane permeability 
will typically exhibit permeation rate limited absorption. Hence, two areas of 
pharmaceutical research that focus on improving the oral bioavailability of active 
agents include: (i) enhancing solubility and dissolution rate of poorly water-soluble 
drugs and (ii) enhancing permeability of poorly permeable drugs. So, solid 
dispersion technologies is used to improve the dissolution characteristics of poorly 
water-soluble drugs and in turn their oral bioavailability.
6
  
 
Solubilization7 
 Solubility is defined as the concentration of the undissolved solid in a solvent 
under a given set of conditions. The solution becomes saturated and the dissolved 
solute is in equilibrium with the excess undissolved solute. 
Poorly water-soluble drugs are increasingly becoming a problem in terms of 
obtaining the satisfactory dissolution within the gastrointestinal tract that is 
necessary for good bioavailability. It is not only existing drugs that cause problems 
but it is the challenge of medicinal chemists to ensure that new drugs are not only 
active pharmacologically but have enough solubility to ensure fast enough 
dissolution at the site of administration, often gastrointestinal tract.
8 
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Dissolution of solid dosage forms in gastrointestinal fluids is a prerequisite 
to the delivery of the drug to the systemic circulation following oral administration.  
Dissolution depends on the solubility of the drug substance in the surrounding 
medium.  Surface area of drug particle is another parameter that influences drug 
dissolution and in turn drug absorption, particle size is a determinant of surface 
area.
9
 
The dissolution of a substance may be described by the modified Noye’s-
Whitney equation; 
Vh / KDS C)-(Cs 
dt
dc
     …1 
Where dc/dt is the rate of increase in C, the concentration of drug in a bulk 
solution in which dissolution of the solid particles is taking place; K is a 
proportionality constant; D is the diffusion coefficient of the drug in the solvent; S is 
the surface area of un dissolved solid; V is the volume of the solution; h is the 
thickness of the diffusion layer around a particle; and Cs is the solubility of the drug 
in the solvent.  If we consider a given drug under well-defined conditions (such as 
controlled liquid intake), we may assume that D, V and h are relatively constant 
values.  Thus we can reduce equation (1) to: 
C)-(Cs KS
dt
dc
      …2 
Equation (2) shows that the two variables, which may be controlled by the 
formulation, are the surface area and the solubility of the drug.  These two variables 
can be altered by the following techniques: 
1. Control the solubility of a weak acid or base by buffering the entire dissolution 
medium, the “microenvironment”, or the diffusion layer surrounding a particle. 
2. Control the solubility of the drug through choice of the physical state, such as 
crystal form, its hydrate and its amorphous form. 
3. Determine the surface area of the drug through control of particle size.10 
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Terms of Appropriate Solubility
11 
 
The approximate solubilities of Pharmacopoeial and National Formulary 
substances are indicated by the descriptive terms in the accompanying table-1.  
Table 1: Terms of solubility 
Descriptive Term Parts of Solvent Required  
for 1 Part of Solute 
Very soluble Less than 1 
Freely soluble From 1 to 10 
Soluble From 10 to 30 
Sparingly soluble From 30 to 100 
Slightly soluble From 100 to 1000 
Very slightly soluble From 1000 to 10,000 
Practically insoluble, or  
Insoluble 
10,000 and over 
 
BCS Classification
12 
According to the BCS, drug substances are classified as follows: 
Class I - High Permeability, High Solubility. 
Class II - High Permeability, Low Solubility. 
Class III - Low Permeability, High Solubility. 
Class IV - Low Permeability, Low Solubility. 
Class boundaries 
 A drug substance is considered highly soluble when the highest dose  
strength is soluble in < 250 ml water over a pH range of 1 to 7.5. 
 A drug substance is considered highly permeable when the extent of 
absorption in humans is determined to be > 90% of an administered dose, 
based on mass-balance or in comparison to an intravenous reference dose. 
 A drug product is considered to be rapidly dissolving when > 85% of the 
labeled amount of drug substance dissolves within 30 minutes using USP 
apparatus I or II in a volume of < 900 ml buffer solutions. 
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Solubilization Techniques
 
to Improve Bioavailability by 
Manufacturing Process
13
 
The three major approaches in overcoming the bioavailability problem are:  
 The Pharmaceutical approach, which involves modification of formulation, 
manufacturing process or the physicochemical properties of the drug without 
changing the chemical structure. 
 The chemical approach in which the pharmacokinetics of the drug is altered 
by modifying its chemical structure. This approach includes salt formation or 
incorporating polar or ionizable groups in the main drug structure resulting in 
the formation of prodrug. 
 The biologic approach where by the route of drug administration may be 
changed such as changing from oral to parentral route. 
The attempts, whether optimizing the formulation, manufacturing process or 
physicochemical properties of the drug, are mainly aimed at enhancement of 
dissolution rate, as it is the major rate-limiting step in the absorption of most drugs. 
Increasing the effective surface are of the drugs will be discussed briefly.  
 
1. Solid dispersions: 
Solid dispersion is drug dispersed in a biologically inert matrix. Drug in 
soluble hydrophilic carrier improves the dissolution rate by reducing particle size, 
higher porosity, drug is in amorphous state, improving wettability and hence 
possibly bioavailability for poorly water soluble drugs. Polymers used are 
polyethylene glycol, polyvinyl pyrollidone of low molecular weight material such as 
sugars. The mechanism of improving dissolution was not yet understood. Recently 
surfactants have been included to stabilize the formulations, this avoiding drug 
recrystallization and potentiating their solubility.
14 
 
2. Nanosizing:  
Reducing drug particle size to below submicron level i.e., 100-200 nm. This 
reduction of particle size leads to significant increase in the dissolution rate of drug. 
Elans nanomilling technology is utilized, which works on two approaches ‘top 
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down’ (Wet milling technology) and ‘bottom up’ (precipitation, crystallization). 
Stabilizers are used to stabilize the nanosupension against inter-particle forces 
between particles due to dispersion or vander walls forces. The inter-particle forces 
are needed to overcome by repulsive forces. There are two modes of imparting 
repulsive forces or energetic barriers to colloidal system. Steric stabilization and 
electrostatic stabilization. Steric stabilization is achieved by adsorbing polymers in 
to particle surface, electrostatic stablization is obtained by adsorbing changed 
molecules, which can be ionic surfactants or charged polymers, on to the particle 
surface. Nanosupension are typically converted to a solid dosage form by spray 
drying process.
15 
 
3. Micronization: 
The process involves reducing the size of the solid drug particles to 1 to10 
microns commonly by spray drying or by use of air attrition methods (fluid energy 
mill). Greater the surface area faster the dissolution. E.g. Griseofulvin, several 
steroidal and sulfa drugs.
 
 
4. Co-grinding of drug with Excipients: 
Particle size reduction is performed by milling in jet miller for poorly soluble 
compound to increase the bioavailability after micronisation of drugs. In co-grinding 
method the large quantities of water soluble polymers are used as an excipient. 
Markus Vogt et al.
16
 assesed the dissolution of poorly soluble drugs albendazole, 
felodipine was improved with various excipients like lactose monohydrate, 
cornstarch, poly vinyl pyrolidone, hydroxy propyl methyl cellulose and sodium 
lauryl sulphate. 
 
5. Lyophilization: 
The material to be dried is first frozen and then subjected under a high 
vacuum to heat and the frozen liquid sublimed leaving only the solid, dried 
components of the original liquid. The four components of freeze driers are vacuum 
chamber for drying, vacuum source, heat source and vapor removal system. Gole et 
al. and Lawrence et al.
17
 described the inventive preparation of lyophilized matrix 
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with gelatin, pectin, soy fibre protein and monitor. The low soluble and bitter actives 
like risperidone and ibuprofen are coated by particulate coating with natural or 
synthetic polymer and organic solvents and dried by vapor removal system.
18
  
 
6. Use of Surfactants:  
The surface-active agents enhance dissolution rate primarily by promoting 
wetting and penetration of dissolution fluid into the solid drug particles. They are 
generally used in concentration below their critical micelle concentration (CMC) 
values since above CMC, the drug entrapped in the micelle structure fails to 
partition in the dissolution fluid. Nonionic surfactants like polysorbates are widely 
used. Examples of drugs whose bioavailability have been increased by use of 
surfactants in the formulation include steroids like spironolactone.  
 
7. Use of Salt forms:  
Salts have improved solubility and dissolution characteristics in comparison 
to the original drug. Alkali metals salts of acidic drug like penicillin’s and strong 
acid salts of basic drugs like atropine are more water-soluble than the parent drug.  
 
8. Alteration of pH of the Drug Microenvironment:  
This can be achieved in two ways – in situ salt formation, and addition of 
buffers too the formulation. E.g. Buffered aspirin tablets.  
 
9. Use of more soluble metastable polymorphs:  
Depending upon the internal structure of the solid drug, selection of proper 
form of drug with greater solubility is important. In general, amorphs are more 
soluble than metastable polymorphs, anhydrates are more soluble than metastable 
polymorphs, anhydrates are more soluble than hydrates and solvates are more 
soluble than solvates. The B form of chlorampheical palmitate is more water-soluble 
than the A and the C forms. 
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10. Solute-solvent complexation: 
  Solvates of drugs with organic solvents (also called as pseudopolymorphs) 
generally have higher aqueous solubility than their respective hydrates or the 
original drug.  
 
11. Solvent deposition: 
In this method, the poorly aqueous soluble drug such as nifedipine is 
dissolved in an organic solvent like alcohol and deposited on an inert, hydrophilic, 
solid matrix such as starch or microcrystalline cellulose by evaporation of solvent.  
 
12. Selective adsorption on insoluble carriers:  
The weak physical bonding between the adsorbate and the adsorbent, and 
hydration and swelling of the clay in the aqueous media. Bentonite can enhance the 
dissolution rate of poorly water-soluble drugs such as griseofulvin, indomethacin 
and prednisolone by maintaining the concentration gradient at its maximum.  
 
13. Molecular encapsulation and cyclodextrins:  
The beta and gamma cyclodextrins and several of their derivatives are unique in 
having the ability to form molecular inclusions complexes with hydrophobic drug 
having poor aqueous solubility.  These cyclodextrin molecules are versatile in 
having a hydrophobic cavity of size suitable enough to accommodate the lipophilic 
drugs as guest; the outside of the host molecule is relatively hydrophilic. Thiazide 
diuretics, arbiturates, benzodiazepines. 
 
Solid Dispersion Technology
 
Definition: 
The term solid dispersion refers to a group of solid products consisting of at 
least two different components, generally a hydrophilic matrix and a hydrophobic 
drug. The matrix can be either crystalline or amorphous. The drug can be dispersed 
molecularly, in amorphous particles (clusters) or in crystalline particles. 
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The enhancement of oral bioavailability of poorly water soluble drugs 
remains one of the most challenging aspects of drug development.  Although salt 
formation, solubilization and particle size reduction have commonly been used to 
increase dissolution rate and bioavailability. There are practical limitations for these 
techniques. The salt formation is not feasible for compounds that are neutral, weakly 
acidic or weakly basic. The solubilization of drugs in organic solvents or in aqueous 
media by the use of surfactants and co solvents leads to liquid formulations that are 
usually undesirable from the view points of patient acceptability and 
commercialization. 
In 1961, Sekiguchi and Obi
19
 developed a practical method whereby many of 
the limitations with the bioavailability enhancement of poorly water-soluble drugs 
can be overcome, which was termed as “Solid Dispersion”16. 
 
  
Poorly water-
soluble drug 
  
     
Tablet/capsule  Dosage form  
Solid dispersion/ 
solution 
     
Disintegration    Disintegration 
     
Large solid particle 
(usually 5-100 
microns) 
 Drug in GI tract  
Colloidal particles/ 
fine oily globules 
(usually <1 micron) 
     
Lower dissolution 
rate 
 
Absorption into  
body system 
 
Higher dissolution 
rate 
 
Fig. 1: A schematic representation of the bioavailability enhancement of a 
poorly water-soluble drug by solid dispersion.
20 
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From conventional capsules/tablets, the dissolution rate is limited by the size 
of the primary particles formed after the disintegration of dosage forms.  In this case, 
an average particle size of 5 m is usually the lower limit, although higher particle 
sizes are preferred for ease of handling, formulation and manufacturing.  On the 
other hand, if a solid dispersion or a solid solution is used, a portion of the drug 
dissolves immediately to saturate the gastrointestinal fluid, the excess drug 
precipitates out as fine colloidal particle or oily globules of submicron size. 
Complexation with cyclodextrins, solubilization of drugs in solvent(s), and 
particle size reduction has been utilized to improve the dissolution rate but, there are 
substantial limitations with each of these techniques.  
Much of the research that has been reported on solid dispersion technologies 
involves drugs that are poorly water-soluble and highly permeable to biological 
membranes as with these drugs dissolution is the rate limiting step to absorption. 
Hence, the hypothesis has been that the rate of absorption in vivo will be 
concurrently accelerated with an increase in the rate of drug dissolution. Therefore, 
solid dispersion technologies are particularly promising for improving the oral 
absorption and bioavailability of BCS Class II drugs
21
. 
 
Historical Background 
 In 1961, a unique approach of solid dispersion to reduce the particle size and 
increase rates of dissolution and absorption was first demonstrated by Sekiguchi and 
Obi.
19
 They proposed the formation of a eutectic mixture of a poorly soluble drug 
such as sulfathiazole with a physiologically inert, easily soluble carrier such as urea.  
The eutectic mixture was prepared by melting the physical mixture of the drug and 
the carrier, followed by a rapid solidification process. Upon exposure to aqueous 
fluids, the active drug was expected to be released into the fluids as fine, dispersed 
particles because of the fine dispersion of the drug in the solid eutectic mixture and 
the rapid dissolution of the soluble matrix. 
 Levy and Kanig
22
 subsequently noted the possibility of using a solid solution 
approach in which a drug is dispersed molecularly in a soluble carrier.  In a series of 
reports in 1965-66, Goldberg et al
23
 presented a detailed experimental and 
theoretical discussion of advantages of solid solution over the eutectic mixture. 
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 In 1965, Tachibana and Nakamaru
24
 reported a novel method for preparing 
aqueous colloidal dispersions of -carotene by using water-soluble polymers such as 
polyvinyl pyrrolidone. They dissolved the drug and the polymer carrier in a common 
solvent and then evaporated the solvent completely. A colloidal dispersion was 
obtained when the coprecipitate was exposed to water. 
 In 1966, Mayersohn and Gibaldi
25
 demonstrated that the dissolution rate of 
griseofulvin could be markedly enhanced when dispersed in polyvinyl pyrrolidone 
by the same solvent method. 
 Chiou and Riegelman
26
 used PEG 6000 as a dispersion carrier. It is believed 
that this relatively new field of pharmaceutical technique and principles will play an 
important role in increasing dissolution, absorption and therapeutic efficacy of drugs 
in future dosage forms. Therefore, a thorough understanding of its fast release 
principles, methods of preparation, selection of suitable carriers, determination of 
physical properties, limitations and disadvantages will be essential in the practical 
and effective application of this approach. 
 
Advantages: 
1. Solid dispersions are used for the improvement of the bioavailability of 
poorly water soluble drugs
27
by  enhance the dissolution of the drug.
28
 
2. Solid dispersions are better than other particle size reducing techniques to 
enhance the solubility, because the other size reduction techniques reduces 
the size to a limit approximately 2-5 microns which doesn’t cause enough 
enhancement in drug solubility or drug release in the small intestine and to 
improve the bioavailability.
29
 
3. Reduce pre-systemic metabolism, this may be due to carrier inhibit the 
enzyme responsible for biotransformation of the drug. 
4. Liquid form of the drug can be transformed to solid form. 
5. The problems of solid powder such as less size of particles shows poor 
mechanical properties (include high adhesion and poor flow properties) can 
be overcome by the use of solid dispersions. 
6. Solid dispersions can be formulated as extended release dosage forms.30 
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Disadvantages: 
1. Amorphous state of a drug may undergo crystallization. 
2. Aging may decrease the dissolution rate and changes in crystallinity. 
3. Solid dispersions may be deteriorated in presence of moisture and excessive 
temperature. The presence of moisture influences the crystallinity of the drug 
and stability issues are complicated.
31-34
Some polymers used in solid 
dispersion are hygroscopic in nature and may absorb moisture that may result 
in the crystal growth. Sometimes the metastable form of drug may be 
changed to stable form. Hence, there may be a decrease in solubility and 
dissolution rate.
35, 36
 
4. It is also difficult to understand the relation between structure of drug and its 
release from solid dispersion. 
5. Difficulty in understanding the physical structure of solid dispersions. 
6. Problem of residual solvents.  
7. Prediction of shelf life of amorphous materials is difficult. 
 
Applications: 
1. To obtain a homogeneous distribution of a small amount of drug. 
2.   To stabilize the unstable drug. 
3. To dispense liquid (up to 10%) or gaseous compounds in a solid dosage. 
4. To formulate a fast release primary dose in a sustained released dosage form. 
5. To formulate sustained release regimen of soluble drugs by using poorly 
soluble or insoluble carriers. 
6. To reduce pre systemic inactivation of drugs like morphine and progesterone. 
7. Polymorphs in a given system can be converted into isomorphous, solid 
solution, eutectic or molecular addition compounds. 
8. Improve exposure (increase bioavailability, more rapid onset, decrease dose) 
9. Reduce variability (Decreased Fed / Fasted effect). 
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Reasons for Improvement of Solubility  
The enhancement in dissolution rate as a result of solid dispersion 
formulation, relative to pure drug varies from as high as 400 folds to less than two-
fold.  Corrigan
37
 reviewed the current understanding of the mechanism of release 
from solid dispersion. The increase in dissolution rate for solid dispersion can be 
attributed to a number of factors.  It is very difficult to show experimentally that any 
one particular factor is more important than another.
38 
The main reasons postulated 
for the observed improvements in dissolution of these systems are as follows. 
 
1. Particles with reduced particle size: Molecular dispersions, as solid dispersions, 
represent the last state on particle size reduction and after carrier dissolution the drug 
is molecularly dispersed in the dissolution medium. Solid dispersions apply this 
principle to drug release by creating a mixture of a poorly water soluble drug and 
highly soluble carriers.
39
 A high surface area is formed, resulting in an increased 
dissolution rate and, consequently, improved bioavailability.
40
 
2. Particles with improved wettability: A strong contribution to the enhancement 
of drug solubility is related to the drug wettability improvement.
41
 Carriers with 
surface activity, such as cholic acid and bile salts can signiﬁcantly increase the 
wettability property of drug.
42
 
3. Particles with higher porosity: Particles in solid dispersions have been found to 
have a higher degree of porosity.
43
 The increase in porosity also depends on the 
carrier properties. For instance, solid dispersions containing linear polymers produce 
larger and more porous particles than those containing reticular polymers and 
therefore, result in a higher dissolution rate.
44
 
4. Drugs in amorphous state: Poorly water soluble crystalline drugs, when in the 
amorphous state tend to have higher solubility.
45
 The enhancement of drug release 
can usually be achieved using the drug in its amorphous state, because no energy is 
required to break up the crystal lattice during the dissolution process.
46
 In solid 
dispersions, drugs are presented as supersaturated solutions after system dissolution, 
and it is speculated that, if drugs precipitate, it is as a metastable polymorphic form 
with higher solubility than the most stable crystal form.
47
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Types of Solid Dispersions 
Based on their molecular arrangement, six different types of solid dispersions can be 
distinguished: 
1. Simple eutectic mixtures 
2. Amorphous precipitation in a crystalline carrier 
3. Solid solutions  
   I. According to their miscibility 
a) Continuous 
b) Discontinuous solid solutions 
II. According to distribution of solvate molecules in the solvendum 
a) Substitutional crystalline solid solutions 
b) Interstitial crystalline solid solutions 
             4. Glass solution and Glass suspension 
 
1. Eutectics:  
 When a mixture of A and B with composition E is cooled, A and B 
crystallize out simultaneously, whereas when other compositions are cooled, one of 
the components starts to crystallize out before the other. Solid eutectic mixtures are 
usually prepared by rapid cooling of a co-melt of the two compounds in order to 
obtain a physical mixture of very fine crystals of the two components. When a 
mixture with composition E, consisting of a slightly soluble drug and an inert, 
highly water soluble carrier, is dissolved in an aqueous medium, the carrier will 
dissolve rapidly, releasing very fine crystals of the drug. The large surface area of 
the resulting suspension should result in an enhanced dissolution rate and thereby 
improved bioavailability.
48 
 
Fig. 2: Phase diagram for a eutectic system 
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2. Amorphous solid solution: 
In an amorphous solid solution, the solute molecules are dispersed 
molecularly but irregularly within the amorphous solvent. Using griseofulvin in 
citric acid, Chiou and Riegelman were the first to report the formation of an 
amorphous solid solution to improve dissolution properties of drugs. Other carriers 
urea and sugars such as sucrose, dextrose and galactose, organic polymers such as 
PVP, PEG and various cellulose derivatives have been utilized for this purpose. 
 
                                         Fig.3: Amorphous Solid Solution 
 
3. Solid solutions: 
According to their miscibility two types of solid solution are:- 
A. Continuous Solid Solutions: 
In a continuous solid solution, the components are miscible in all 
proportions. Theoretically, this means that the bonding strength between the two 
components is stronger than the bonding strength between the molecules of each of 
the individual components. Solid solutions of this type have not been reported in the 
pharmaceutical literature to date. 
B. Discontinuous solid solutions: 
In the case of discontinuous solid solutions, the solubility of each of the 
components in the other component is limited. A typical phase diagram, show the 
regions of true solid solutions. In these regions, one of the solid components is 
completely dissolved in the other solid component. Below a certain temperature, the 
mutual solubilities of the two components start to decrease. According to Goldberg
48
  
the term solid solution should only be applied when the mutual solubility of the two 
components exceeds 5%. 
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Fig.4: Phase Diagram for Discontinuous Solid Solution 
 
According to the way in which the solvate molecules are distributed in the 
solvendum the two type of solid solution are:- 
A. Substitutional Solid Solutions: 
A substitutional crystalline solid dispersion is a type of solid solutions which 
have a crystalline structure, in which the solute molecules substitute for solvent 
molecules in the crystal lattice. Substitution is only possible when the size of the 
solute molecules differs by less than 15% or so from that of the solvent molecules.
49
 
 
Fig.5:  Substitutional Crystalline Solid Solution 
 
B. Interstitial Crystalline Solid Solutions: 
In interstitial solid solutions, the dissolved molecules occupy the interstitial 
spaces between the solvent molecules in the crystal lattice. As in the case of 
substitutional crystalline solid solutions, the relative molecular size is a crucial 
criterion for classifying the solid solution type. In the case of interstitial crystalline 
solid solutions, the solute molecules should have a molecular diameter that is no 
greater than 0.59 of the solvent molecule's molecular diameter. Furthermore, the 
volume of the solute molecules should be less than 20% of the solvent.
50 
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                                   Fig.6: Interstitial Crystalline Solid Solution 
 
4.  Glass Solutions and Glass Suspensions: 
Chiou and Riegelman
26
 first introduced the concept of formation of a glass 
solution as another potential modification of dosage forms in increasing drug 
dissolution and absorption. A glass solution is a homogenous, glassy system in 
which a solute dissolves in a glassy solvent. The term glass can be used to describe 
either a pure chemical or a mixture of chemicals in a glassy or vitreous state. The 
glassy or vitreous state is usually obtained by an abrupt quenching of the melt. It is 
characterized by transparency & brittleness below the glass transition temperature 
Tg. 
 
Methods of Preparation 
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1. Melting Method (Fusion Method): 
The melting or fusion method, involves the preparation of physical mixture 
of a drug and a water-soluble carrier and heating it directly until it melted. The 
melted mixture is then solidified rapidly in an ice-bath under vigorous stirring. The 
final solid mass is crushed, pulverized and sieved. However many substances, either 
drugs or carriers, may decompose or evaporates during the fusion process which 
employs high temperature. Some of the means to overcome these problems could be 
heating the physical mixture in a sealed container or melting it under vacuum or in 
presence of inert gas like nitrogen to prevent oxidative degradation of drug or 
carrier.
26 
2. Melt Extrusion Method: 
Melt extrusion method is same as the melt method except that intense mixing 
of drug/carrier mix is typically processed with a twin-screw extruder. The 
drug/carrier mix is simultaneously melted, homogenized and then extruded and 
shaped as tablets, granules, pellets, sheets, sticks or powder. The intermediates can 
then be further processed into conventional tablets. An important advantage of the 
hot melt extrusion method is that the drug/carrier mix is only subjected to an 
elevated temperature for about 1 min, which enables drugs that are somewhat 
thermo labile to be processed.
51, 52
 
3. Solvent Evaporation Method: 
In this method, the first step is formation of solution containing physical 
mixture of the drug and carrier dissolved in a common solvent and second step 
involve the removal of solvent resulting the formation of solid dispersion. This 
enabled them to produce a solid solution of the highly lipophilic drug in the highly 
water soluble carrier PVP. An important prerequisite for the manufacture of a solid 
dispersion using the solvent method is that both the drug and the carrier are 
sufficiently soluble in the solvent. The solvent can be removed by various methods 
like by spray-drying or by freeze-drying. Temperatures used for solvent evaporation 
generally lie in the range 23-65 °C.
53
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4. Melting Solvent Method (Melt Evaporation): 
It involves preparation of solid dispersions by dissolving the drug in a 
suitable liquid solvent and then incorporating the solution directly into the melt of 
polyethylene glycol, which is then evaporated until a clear, solvent free film is left. 
The film is further dried to constant weight. The 5 –10% (w/w) of liquid compounds 
can be incorporated into polymer without significant loss of its solid property. It is 
possible that the selected solvent or dissolved drug may not be miscible with the 
melt of the polymer. Also the liquid solvent used may affect the polymorphic form 
of the drug, which precipitates as the solid dispersion. From a practical standpoint, it 
is only limited to drugs with a low therapeutic dose e.g. below 50 mg.
54
 
 
5. Physical Mixture Method:  
The physical mixtures were prepared by weighing the calculated amount of 
drug and carriers and then mixing them in a glass mortar by triturating. The resultant 
physical mixtures were passed through 44-mesh sieve and stored in desiccators until 
used for further studies.
55
 
 
6. Co-Grinding Method: 
The calculated amounts of drug and carriers where weighed and mixed 
together with one ml of water. The damp mass obtained was passed through a sieve. 
The resultant granules were dispersed in petri dishes and dried at 60°C under 
vacuum, until a constant weight was obtained. The granules obtained were stored in 
desiccators until used for further studies. 
 
7. Co-precipitation method:  
Solute and solid carrier solvent are dissolved in a common volatile liquid 
solvent such as alcohol. The liquid solvent is removed by evaporation under reduced 
pressure or by freeze drying which result in amorphous precipitation of solute in a 
crystalline carrier. E.g: amorphous sulfathiazole in crystalline urea. Such dispersions 
are often called as co-evaporates or co-precipitates.  
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Alternative Strategies: 
 
1. Lyophilisation Technique/ Freeze-drying/ Cryodessication: 
Freeze-drying involves transfer of heat and mass to and from the product 
under preparation. Lyophilisation has been thought of a molecular mixing technique 
where the drug and carrier are co-dissolved in a common solvent, frozen and 
sublimed to obtain a lyophilized molecular dispersion.
56
 Lyophilization is carried out 
by sublimation in which the transition of a substance from the solid to the vapor 
state, without first passing through an intermediate liquid phase. 
 Freeze Drying Involves Four Steps: 
 Pretreatment 
 Freezing 
 Primary Drying 
 Secondary Drying 
 
Pretreatment:  
Pretreatment includes any method of treating the product prior to freezing. 
This may include concentrating the product, formulation revision (addition of 
components to increase stability and/or improve processing), decreasing a high 
vapor pressure solvent or increasing the surface area.  
Freezing: 
  In this step, it is important to cool the material below its triple point, the 
lowest temperature at which the solid and liquid phases of the material can co-exist. 
This ensures that sublimation rather than melting will occur in the following steps.  
Primary Drying: 
  During this drying phase, the pressure is lowered and enough heat is supplied 
to the material for the water to sublime. In the initial drying phase, about 95% of the 
water in the material is sublimated. 
Secondary Drying:  
The secondary drying phase aims to remove unfrozen water molecules, since 
the ice was removed in the primary drying phase. In this phase, the temperature is 
raised higher than in the primary drying phase, and can even be above 0 °C, to break 
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any physico-chemical interactions that have formed between the water molecules 
and the frozen material. At the end of the operation, the final residual water content 
in the product is extremely low, around 1% to 4%. 
Advantages: 
1. Product is dried without elevated temperatures. 
2. Rapid reconstitution time. 
3. Constituents of the dried material remain homogenously dispersed. 
4. Sterility of product can be achieved and maintained. 
Disadvantages: 
1. Volatile compounds may be removed by high vacuum. 
2. Most expensive unit operation. 
3. Stability problems associated with individual drugs. 
 
2. Electrostatic Spinning Method: 
This technology used in the polymer industry combines solid 
solution/dispersion technology with nanotechnology.
57
 Electro spinning is a process 
in which solid fibers are produced from a polymeric fluid stream solution or melt 
delivered through a millimeter-scale nozzle. In this process, a liquid stream of a 
drug/polymer solution is subjected to a potential between 5 and 30 kV. When 
electrical forces overcome the surface tension of the drug/polymer solution at the air 
interface, fibers of submicron diameters are formed. They are collected on a screen 
to give a nonwoven fabric, or on a spinning mandril. The fiber diameters depend on 
surface tension, dielectric constant, feeding rate, and electric field strength.
58
 Water-
soluble polymers would be useful in the formulation of immediate release dosage 
forms, and water-insoluble polymers in controllable dissolution properties. 
 
3. Super Critical Fluid Technology: 
This technology has been introduced in the late 1980s and early 1990s. SCFs 
either as solvent: rapid expansion from supercritical solution (RESS) or antisolvent: 
gas antisolvent (GAS), supercritical antisolvent (SAS), solution enhanced dispersion 
by supercritical fluids (SEDS) and/or dispersing fluid: GAS, SEDS, particles from 
gas-saturated solution (PGSS). The spray drying, solvent evaporation and hot melt 
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method often result in low yield, high residual solvent content or thermal 
degradation of the active substance. In the supercritical fluid carbon dioxide is used 
as either a solvent for drug and matrix or as an anti-solvent.
59
  
When supercritical CO2 is used as solvent, matrix and drug are dissolved and 
sprayed through a nozzle, into an expansion vessel with lower pressure and particles 
are immediately formed. The adiabatic expansion of the mixture results in rapid 
cooling. This technique does not require the use of organic solvents and since CO2 is 
considered environmentally friendly, this technique is referred to as ‘solvent free’. 
However, the application of this technique is very limited, because the solubility in 
CO2 of most pharmaceutical compounds is very low (<0.01 %wt)
 60
and decreases 
with increasing polarity.  
 
Selection of a Carrier
38
: 
 The properties of the carrier have a major influence on the dissolution 
characteristics of the dispersed drug.  A carrier should meet the following criteria to 
be suitable for increasing the dissolution rate of a drug. 
1. Be freely water-soluble with intrinsic rapid dissolution properties. 
2. Be non-toxic and pharmacologically inert. 
3. Be heat stable with a low melting point for the melt method. 
4. Be soluble in a variety of solvents and pass through a vitreous state upon 
solvent evaporation for the solvent method. 
5. Be able to preferably increase the aqueous solubility of the drug and 
6. Be chemically compatible with the drug and not form a strongly bonded 
complex with the drug. 
 
                         
 
 
 
 
 
 
 
 
22 
 
Table 2: Materials used as carrier for solid dispersion 
Sugars Dextrose, sucrose, galactose, sorbitol, maltose, 
xylitol, mannitol, lactose. 
Acids Citric acid, succinic acid 
Polymeric 
materials 
Povidone (PVP), polyethylene glycol (PEG), 
hydroxypropyl methyl cellulose (HPMC), 
methyl cellulose, hydroxy ethyl cellulose 
(HEC), cyclodextrin, hydroxy propyl cellulose 
(HPC), pectin, galactomannan. 
Insoluble or 
enteric polymer 
Hydroxy propyl methyl cellulose phthalate, 
eudragit L100, eudragit S100, Eudragit RL, 
Eudragit RS. 
Surfactants Polyoxyethylene stearate, renex, poloxamer 
188, texafor AIP, deoxycholic acid, tweens, 
spans. 
Miscellaneous Pentaerythritol, pentaerythrityl tetraacetate, 
urea, urethane, hydroxy alkyl xanthins 
 
Carriers 
1. Polyethylene glycol (PEG) 
General characteristics of PEGs Polyethylene glycols (PEG) are polymers of 
ethylene oxide, with a molecular weight (MW) usually falling in the range 200 –  
3,00,000. For the manufacture of solid dispersions and solutions, PEGs with 
molecular weights of 1500 - 20,000 are usually employed. As the MW increases, so 
does the viscosity of the PEG. At MW up to 600, PEGs are fluid, in the range 800-
1500 they have a consistency that is best described as Vaseline-like, from 2000 to 
6000 they are waxy and those with MW of 20 000 and above form hard, brittle 
crystals at room temperature. Their solubility in water is generally good, but 
decreases with MW. A particular advantage of PEGs for the formation of solid 
dispersions is that they also have good solubility in many organic solvents.  
The melting point of the PEGs of interest lies under 65
o
C in every case (e.g. the m.p. 
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of PEG 1000 is 30-40
o
C, the m.p. of PEG 4000 is 50-58
o
C and the m.p. of PEG 20 
000 is 60-63ºC).
61
 These relatively low melting points are advantageous for the 
manufacture of solid dispersions by the melting method. Additional attractive 
features of the PEGs include their ability to solubilize some compounds
62
 and also to 
improve compound wettability. Even the dissolution rate of a relatively soluble drug 
like aspirin can be improved by formulating it as a solid dispersion in PEG 6000.
63
 
PEGs of MW 4000-6000 are the most frequently used for the manufacture of solid 
dispersions, because in this MW range the water solubility is still very high. 
The drug/carrier ratio in a solid dispersion is one of the main influences on the 
performance of a solid dispersion. If the percentage of the drug is too high, it will 
form small crystals within the dispersion rather than remaining molecularly 
dispersed. On the other hand, if the percentage of the carrier is very high, this can 
lead to the complete absence of crystallinity of the drug and thereby enormous 
increases in the solubility and release rate of the drug.
64
 
 
2. Polyvinylpyrrolidone (PVP) 
General characteristics of PVP polymerization of vinylpyrrolidone lead to 
PVP of molecular weights ranging from 2500 to 3,00,0000. Similarly to the PEGs, 
PVPs have good water solubility and can improve the wettability of the dispersed 
compound in many cases. Improved wetting and thereby an improved dissolution 
rate from a solid dispersion in PVP has been demonstrated for flufenamic acid
65
.  
The aqueous solubility of the PVPs becomes poorer with increasing chain length and 
a further disadvantage of the high MW PVPs is their much higher viscosity at a 
given concentration.
66
 Similarly to PEG, solid dispersions prepared with high 
proportions of PVP tend to exhibit higher drug solubility and release rate than those 
with high proportions of drug. 
3. Polyvinylalcohol (PVA), crospovidone (PVP-CL), 
polvinylpyrrolidone-polyvinylacetate copolymer (PVP-PVA): 
 All three polymers belong to the polyvinyl group. Whereas PVA and PVP-
PVA copolymers are both water soluble, crospovidone swells when dispersed in 
water.
67 
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4. Cellulose Derivatives: 
General characteristics of cellulose derivatives - Celluloses are naturally 
occurring polysaccharides that are ubiquitous in the plant kingdom. They consist of 
high molecular weight unbranched chains, in which the saccharide units are linked 
by b-1, 4-glycoside bonds. 
 
5. Hydroxypropylmethylcellulose (HPMC):  
HPMCs are mixed ethers of cellulose, in which 16.5-30% of the hydroxyl 
groups are methylated and 4-32% are derivatized with hydroxypropyl groups. The 
molecular weight of the HPMCs ranges from about 10,000 to 1,500,000 and they are 
soluble in water and mixtures of ethanol with dichloromethane and methanol with 
dichloromethane.
68
 
 
6. Hydroxypropylcellulose (HPC): 
HPC exhibits good solubility in a range of solvents, including water (up till 
40ºC), ethanol, methanol and chloroform. The average MW of the HPCs ranges 
from 37,000 (Type SSL) to 1,150,000 (Type H).
69
 Several  studies were carried  on 
the influence of the chain length and proportion of HPC in the solid dispersion on 
the release behavior of  flurbiprofen. The release rate improved as the proportion of 
HPC was increased and when lower MW HPCs were used as the carrier. 
 
7. Carboxymethylethylcellulose (CMEC): 
  CMEC also belongs to the cellulose ethers, but unlike many of the others it is 
resistant to dissolution under gastric (acidic) conditions. It dissolves readily at pH 
values above 5-6, with lowest dissolution pH being dependent on the grade of the 
CMEC. CMECs also dissolve readily in acetone, isopropanol 70%, ethanol 60% and 
1:1 mixtures of dichloromethane and ethanol. Amorphous solid dispersions of 
nifedipine and spironolactone show enormous increases in the dissolution rate of the 
drug at pH values of 6.8
70
. Likewise, the bioavailability of the test substance MFB-
1041 could be substantially improved in beagles.
71
 
 
 
 
25 
 
8. Urea: 
Urea is the end product of human protein metabolism, has a light diuretic 
effect and is regarded as non-toxic. Its solubility in water is greater than 1 in 1 and it 
also exhibits good solubility in many common organic solvents. Although urea is 
not often used as a carrier these days, it has been recently shown that the dissolution 
rate of the poorly soluble compound ofloxacin can be improved by more than 
threefold by incorporating it in a co evaporate with urea.
72
 
 
9. Sugar, Polyols and their Polymers: 
  Although sugars and related compounds are highly water soluble and have 
few, if any, toxicity issues, they are less suitable than other carriers for the 
manufacture of solid dispersions. The melting point of most sugars is high, making 
preparation by the hot melt method problematic, and their solubility in most organic 
solvents is poor, making it difficult to prepare co evaporates. 
 
10. Emulsifiers: 
The release behavior of many drugs can also be improved through the use of 
emulsifying agents. Two mechanisms are possible here: improvement of wetting 
characteristics and solubilization of the drug. Owing to their potential toxicity 
problems, such as damage to mucosal surfaces, they are usually used in combination 
with another carrier.
73
 
 
11. Organic acids and their derivatives: 
Organic acids such as succinic acid and citric acid have been used as carriers 
in solid dispersions, originally to enhance the release rate of griseofulvin.
23, 26
 
 
12. Cyclodextrins:  
Cyclodextrins are primarily used to enhance solubility, chemical protection, 
taste masking and improved handling by the conversion of liquids into solids by 
entrapment.
38
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Advantages of cyclodextrins: 
 Increasing the stability of the drug. 
 Release profile during gastrointestinal transit through modification of drug 
release site and time profile. 
 Decreasing local tissue irritation. 
 Masking unpleasant taste. 
 
Future Prospects 
 Despite many advantages of solid dispersion, issues related to preparation, 
reproducibility, formulation, scale up and stability limited its use in commercial 
dosage forms for poorly water-soluble drugs. Successful development of solid 
dispersion systems for preclinical, clinical and commercial use has been feasible in 
recent years due to the availability of surface-active and self-emulsifying carriers 
with relatively low melting points. The preparation of dosage forms involves the 
dissolving of drug and carriers in solvent and filling into hard gelatin capsules or 
compressed into tablets. Because of the simplicity of manufacturing and scale up 
processes, the physicochemical properties, as a result the bioavailability of solid 
dispersions is not expected to change significantly during the scale up. For this 
reason, the popularity of the solid dispersion system to solve difficult bioavailability 
issues with respect to poorly water soluble drugs will grow rapidly. Because the 
dosage form can be developed and prepared using small amounts of drug substances 
in early stages of the drug development process, the system might have an advantage 
over such other commonly used bioavailability enhancement techniques as 
micronization and lyophilization of drugs. 
 One major focus of future research will be the identification of new surface-
active and self-emulsifying carriers for solid dispersion.  Only a small number of 
such carriers are currently available for oral use.  Some carriers that are used for 
topical application of drug only may be qualified for oral use by conducting 
appropriate toxicological testing.  One limitation in the development of solid 
dispersion systems may the inadequate drug solubility in carrier, so a wider choice 
of carriers will increase the success of dosage form development. Research should 
also be directed toward identification of vehicles or excipients that would retard or 
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prevent crystallization of drugs from super-saturated systems. Attention must be 
given to any physiological and pharmacological effects of carriers used. Many of the 
surface-active and self-emulsifying carriers are lipid in nature, so potential roles of 
such carriers on drug absorption, especially on their inhibitory effects on CYP-3 
based drug metabolism and p-glycoprotein-mediated drug efflux will require careful 
consideration. 
 In addition to bioavailability enhancement, much recent research on solid 
dispersion systems was directed toward the development of extended-release dosage 
forms. 
 Physical and chemical stability of both the drug and the carrier in a solid 
dispersion are major developmental issues, an exemplified by the recent withdrawal 
of ritonavir capsules from the market, so future research needs to be directed to 
address various stability issues.  The semisolid and waxy nature of solid dispersions 
poses unique stability problems that might not be seen in other types of solid dosage 
forms.  Predictive methods will be necessary for the investigation of any potential 
crystallization of drugs and its impact on dissolution and bioavailability, possible 
drug-carrier interactions must also be investigated.
74 
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Osteoporosis 
Osteoporosis is a disease characterized by low bone mass and loss of bone 
tissue that may lead to weak and fragile bones. Osteoporosis, leads to increased risk 
for fractured bones (broken bones), particularly in the hip, spine, and wrist. 
Osteoporosis is often considered to be a condition that frail elderly women develop. 
However, the damage from osteoporosis begins much earlier in life. Because peak 
bone density is reached at approximately 25 years of age, it is important to build 
strong bones by that age, so that the bones will remain strong later in life. Adequate 
calcium intake is an essential part of building strong bones. 
According to the World Health Organization, the prevalence of osteoporosis 
among U.S. white women post menopause is estimated to be 14% in those 50-59 
years of age, 22% in those 60-69 years of age, 39% in those 70-79 years of age and 
70% in those 80 years of age and older. Significant risk has been reported in people 
of all ethnic backgrounds. White and Asian racial groups, however, are at greatest 
risk.
75 
 Causes: 
Osteoporosis occurs when there is an imbalance between new bone 
formation and old bone resorption. The body may fail to form enough new bone, or 
too much old bone may be reabsorbed, or both. Two essential minerals for normal 
bone formation are calcium and phosphate.  
The leading cause of osteoporosis is a lack of certain hormones, particularly 
estrogen in women and androgen in men. Women, especially those older than 60 
years of age, are frequently diagnosed with the disease. Menopause is accompanied 
by lower estrogen levels and increases a woman's risk for osteoporosis. Other factors 
that may contribute to bone loss in this age group include inadequate intake of 
calcium and vitamin D, lack of weight-bearing exercise, and other age-related 
changes in endocrine functions (in addition to lack of estrogen). 
Other conditions that may lead to osteoporosis include overuse of 
corticosteroids (Cushing syndrome), thyroid problems, lack of muscle use, bone 
cancer, certain genetic disorders, use of certain medications, and problems such as 
low calcium in the diet. 
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The following are risk factors for osteoporosis: 
 Women are at a greater risk than men, especially women who are thin or 
have a small frame, as are those of advanced age. 
 Women those with a family history of osteoporosis, have a greater risk of 
developing osteoporosis than other women. 
 Postmenopausal women including those who have had early or 
surgically induced menopause, or abnormal or absence of menstrual periods 
are at greater risk. 
 Cigarette smoking, eating disorders such as anorexia nervosa or bulimia, low 
amounts of calcium in the diet, heavy alcohol consumption, inactive lifestyle, 
and use of certain medications, such as corticosteroids and anticonvulsants, 
are also risk factors. 
 Rheumatoid arthritis itself is a risk factor for osteoporosis. 
 Having a parent that has/had osteoporosis is a risk factor for the offspring. 
  
Symptoms: 
Early in the course of the disease, osteoporosis may cause no symptoms. 
Later, it may cause dull pain in the bones or muscles, particularly low back 
pain or neck pain. Later in the course of the disease, sharp pains may come on 
suddenly. The pain may not radiate (spread to other areas); it may be made worse by 
activity that puts weight on the area, may be accompanied by tenderness, and 
generally begins to subside in one week. Pain may linger more than three months. 
People with osteoporosis may not even recall a fall or other trauma that 
might cause a broken bone, such as in the spine or foot. Spinal compression 
fractures may result in loss of height with a stooped posture (called 
adowager’s).Fractures at other sites, commonly the hip or bones of the wrist, usually 
result from a fall. 
 Treatment: 
Treatment for osteoporosis focuses on slowing down or stopping the mineral 
loss, increasing bone density, preventing bone fractures, and controlling the pain 
associated with the disease. 
 
CHAPTER 3 
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Raloxifene Hydrochloride 
 
 
Chemical Nomenclature:  
2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-
benzothiophen-6-ol. 
 
Chemical Formula: C28H27NO4S 
Structure:     
 
 
Molecular weight:  473.583 
 
Description 
A second generation selective estrogen receptor modulator (SERM) used to 
prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on 
bone and cholesterol metabolism but behaves as a complete estrogen antagonist on 
mammary gland and uterine tissue 
 
Physical Properties     :  Off white to pale yellow crystals. 
 
Solubility                      :  Very sparingly soluble in water (0.25mg/ml) 
 
Melting Point               : 143-147ºC 
 
Indication 
For prevention and treatment of osteoporosis in post-menopausal women, as 
well as prevention and treatment of corticosteroid-induced bone loss. Also for the 
reduction in the incidence of invasive breast cancer in postmenopausal women with 
osteoporosis or have a high risk for developing breast cancer. 
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Mechanism of action 
Raloxifene binds to estrogen receptors, resulting in differential expression of 
multiple estrogen-regulated genes in different tissues. Raloxifene produces estrogen-
like effects on bone, reducing resorption of bone and increasing bone mineral 
density in postmenopausal women, thus slowing the rate of bone loss. The 
maintenance of bone mass by raloxifene and estrogens is, in part, through the 
regulation of the gene-encoding transforming growth factor-β3 (TGF-β3), which is a 
bone matrix protein with antiosteoclastic properties. Raloxifene activates TGF-β3 
through pathways that are estrogen receptor-mediated but involve DNA sequences 
distinct from the estrogen response element. The drug also binds to the estrogen 
receptor and acts as an estrogen agonist in preosteoclastic cells, which results in the 
inhibtion of their proliferative capacity. This inhibition is thought to contribute to 
the drug's effect on bone resorption. Other mechanisms include the suppression of 
activity of the bone-resorbing cytokine interleukin-6 promoter activity. Raloxifene 
also antagonizes the effects of estrogen on mammary tissue and blocks uterotrophic 
responses to estrogen. By competing with estrogens for the estrogen receptors in 
reproductive tissue, raloxifene prevents the transcriptional activation of genes 
containing the estrogen response element. As well, raloxifene inhibits the estradiol-
dependent proliferation of MCF-7 human mammary tumor cells in vitro. The 
mechansim of action of raloxifene has not been fully determined, but evidence 
suggests that the drug's tissue-specific estrogen agonist or antagonist activity is 
related to the structural differences between the raloxifene-estrogen receptor 
complex (specifically the surface topography of AF-2) and the estrogen-estrogen 
receptor complex. Also, the existence of at least 2 estrogen receptors (ERα, ERβ) 
may contribute to the tissue specificity of raloxifene.
76 
 
Pharmacokinetics
77
  
Absorption  
Raloxifene is rapidly absorbed from the gastrointestinal tract and undergoes 
extensive first-pass glucuronidation. Approximately 60% of an oral dose is 
absorbed; however, because of extensive presystemic glucuronide conjugation, 
absolute bioavailability is only 2%. Significant interpatient differences in 
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bioavailability may result from alterations in the rate of glucuronide formation and 
enterohepatic recycling. 
 
Distribution 
Raloxifene is widely distributed into tissues; the volume of distribution (V) 
is 2348 L/kg after administration of a single oral dose of 30-150 mg. V is not dose 
dependent. Studies with radioactively labeled raloxifene indicate extensive 
distribution into the liver, serum, lungs, and kidneys. Conversion of the drug to an 
active metabolite appears to occur in several tissues, including the liver, lungs, 
spleen, bone, uterus, and kidneys. Raloxifene and its conjugates are 95% bound to 
albumin and a 1-acid glycoprotein invitro.  Raloxifene does not bind to sex steroid- 
binding globulin.
 
 Although it is unknown whether raloxifene is distributed into 
breast milk, its high protein-binding profile should theoretically limit such 
distribution. Nevertheless, lactating women should not use raloxifene. Raloxifene is 
a pregnancy category X drug and is therefore contraindicated in pregnant women. 
 Metabolism:  
Raloxifene undergoes extensive first-pass metabolism.
 
Conjugate formation 
includes Raloxifene 4’-glucuronide, 6-glucuronide and 6, 4’-diglucuronide. Very 
small amounts of free raloxifene (<1% of a dose) are detected in the circulation. The 
absence of other metabolites suggests that raloxifene is not metabolized by the 
cytochrome P-450 isoenzyme system. Although raloxifene may be converted back 
within certain tissues, reconversion to the parent compound does not appear to occur 
in major target organs, such as the uterus and skeleton. Therefore, it appears that the 
tissue selectivity of raloxifene is not explained by deconjugation of metabolites to 
the parent compound in different tissues. The terminal log linear portions of plasma 
concentration curves for raloxifene and its conjugates are parallel. 
The clearance of raloxifene hydrochloride 400 mg/day given for five days to 
healthy premenopausal women was 51.5-128.3 L/hr/kg, depending on the phase of 
the menstrual cycle.
 
 A mean steady-state V of 4135 L/kg was observed for the 
women. There is no evidence to date to suggest significant influences of sex, race 
and age (42-84 years) on the clearance of raloxifene. The half-life (t1/2) of raloxifene 
at steady state ranges from 15.8 to 86.6 hours and averages 32.5 hours. One study 
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evaluated the t1/2 of raloxifene in 14 healthy postmenopausal women and 14 healthy 
men. The t1/2 ranged from 11 to 27 hours. The oral clearance of a single dose of 
raloxifene is 44.1 L/ hr/kg. The t1/2of raloxifene may be prolonged to 27.7 hours, 
secondary to reverse systemic metabolism and enterohepatic recycling, when the 
drug is given on a long-term basis. 
Excretion: 
 Raloxifene is excreted primarily in the feces. Glucuronide metabolites are 
eliminated in the biliary tract, and are subsequently broken down by bacteria to the 
parent drug. Less than 0.2% of raloxifene is excreted unchanged in the urine; less 
than 6% is excreted in the urine as glucuronide conjugates. 
 
 Pharmacodynamics 
 Raloxifene, a selective estrogen receptor modulator (SERM) of the 
benzothiophene class, is similar to tamoxifen in that it produces estrogen-like effects 
on bone and lipid metabolism, while antagonizing the effects of estrogen on breast 
and uterine tissue. Raloxifene differs chemically and pharmacologically from 
naturally occuring estrogens, synthetic steroidal and nonsteroidal compounds with 
estrogenic activity, and antiestrogens. Estrogens play an important role in the 
reproductive, skeletal, cardiovascular, and central nervous systems in women, and 
act principally by regulating gene expression. When estrogen binds to a ligand - 
binding domain of the estrogen receptor, biologic response is initiated as a result of a 
conformational change of the estrogen receptor, which leads to gene transcription 
through specific estrogen response elements of target gene promoters. The 
subsequent activation or repression of the target gene is mediated through two 
distinct trans activation domains of the receptor: AF-1 and AF-2. The estrogen 
receptor also mediates gene transcription using different response elements and 
other signaling pathways. The role of estrogen as a regulator of bone mass is well 
established. In postmenopausal women, the progressive loss of bone mass is related 
to decreased ovarian function and a reduction in the level of circulation estrogens. 
Estrogen also has favorable effects on blood cholesterol. 
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Current Therapy Options 
Selective estrogen receptor modulators (SERMs).  SERMs demonstrate 
tissue-selective activities that produce estrogenic actions in certain organs (e.g bone, 
brain, and liver) during postmenopausal HRT. The 3 SERMs that are approved by 
FDA include tamoxifen, raloxifene, and toremifene. Although these drugs have 
demonstrated numerous benefits, they are also associated with very serious side 
effects, such as an increased risk of endometrial cancer, which limit their utility.
78, 79
 
Tamoxifen and toremifene are approved for the treatment of various types of 
breast cancer, whereas raloxifene is the only SERM currently approved by FDA for 
the treatment and prevention of postmenopausal osteoporosis, as well as for the 
reduction in risk of invasive breast cancer.
80
 Raloxifene slows bone thinning and 
causes a slight increase in bone thickness. It also decreases resorption of bone and 
reduces biochemical markers of bone turnover to the premenopausal range. These 
effects on bone are manifested as reductions in serum and urine levels of bone 
turnover markers, decreases in bone resorption based on radiocalcium kinetics 
studies, increases in BMD, and decreases in incidence of fractures. Several clinical 
studies have demonstrated that administration of raloxifene 60 mg/d is effective in 
treating postmenopausal osteoporosis. Postmenopausal women either with or 
without prevalent vertebral fractures who were evaluated in the Multiple Outcomes 
of Raloxifene Evaluation (MORE) study demonstrated a reduction of 30% to 50% in 
the occurrence of incident vertebral fractures.
81
 The Continuing Outcomes Relevant 
to Evista (CORE) trial analyzed the long-term skeletal effects of raloxifene. The 
study reported a 30% to 40% reduction in markers of bone turnover after 1 year. 
Investigators observed a 2% to 3% increase in lumbar spine and femoral neck BMD 
after 3 years.
82
 
Role in Therapy: 
Raloxifene carries FDA-approved labeling for use in the prevention and 
treatment of osteoporosis in post-menopausal women. Clinical evidence suggests 
that raloxifene increases bone mineral density, decreases the risk of vertebral 
fractures, potentially prevents breast cancer, and has no significant effect on 
endometrial tissue growth. In addition, raloxifene has positive effects on LDL 
cholesterol and total cholesterol, although data on effects on cardiovascular 
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morbidity and mortality are not yet available. Raloxifene may be used as an 
alternative to traditional hormone replacement therapy for osteoporosis, especially in 
women with a high risk of breast cancer. Raloxifene is an appropriate choice for 
women who cannot tolerate the adverse effects of estrogen or in women who decline 
estrogen therapy. However, raloxifene should not be used in women experiencing 
hot flashes as a primary symptom of estrogen deficiency or in those with a history of 
venous thromboembolism. 
Each treatment decision should be based on the individual patient. Other 
agents (such as bisphosphonates and calcitonin) are available for women with 
osteoporosis who are primarily interested in bone-related benefits. 
Ultimately, it will be information on cardiovascular or breast cancer benefits 
that will determine the future role of raloxifene. Trials assessing these possibilities 
are ongoing and should provide health care providers with more complete 
information on the advantages of raloxifene, if any, over standard hormone 
replacement therapy. 
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Excipients 
 
Polyethylene Glycol 
 
1. Non-proprietary Names 
BP: Macrogols 
2. Synonyms 
         Carbowax; Carbowax Sentry; Lipoxol; Lutrol E; macrogola; PEG; Pluriol E; 
polyoxyethylene glycol. 
3. Empirical Formula and Molecular Weight 
HOCH2 (CH2OCH2)m CH2OH where m represents the average number of 
oxyethylene groups, molecular weight 6000. 
4. Functional Category 
Ointment base; plasticizer; solvent; suppository base; tablet and capsule lubricant. 
5. Applications 
 Pharmaceutical formulations, including parenteral, topical, 
ophthalmic, oral, and rectal preparations. Polyethylene glycol has been used 
experimentally in biodegradable polymeric matrices used in controlled-
release systems. 
 Polyethylene glycols can also be used to enhance the aqueous 
solubility or dissolution characteristics of poorly soluble compounds by 
making solid dispersions with an appropriate polyethylene glycol. 
 Polyethylene glycol grades with molecular weights of 6000 and 
above can be used as lubricants, particularly for soluble tablets. The lubricant 
action is not as good as that of magnesium stearate and stickiness may 
develop if the material becomes too warm during compression. An 
antiadherent effect is also exerted, again subject to the avoidance of 
overheating. 
6. Description 
            The USP32–NF27 describes polyethylene glycol as being an addition 
polymer of ethylene oxide and water. Polyethylene glycol grades 200–600 are 
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liquids; grades 1000 and above are solids at ambient temperatures. 
            Grades of PEG 6000 and above are available as free flowing milled powders. 
7. Typical Properties 
Type of PEG 6000 -- Density (g/cm
3
) --1.080 
 Freezing point (8 
0
C) -- 55–61 
 Viscosity (kinematic) [mm2/s (CST)] -- 250–390 
 Melting point -- 55–638 0C 
Moisture content -- hygroscopicity decreases with increasing molecular weight. 
Solid grades e.g. PEG 4000 and above are not hygroscopic. 
Solubility:  All grades of polyethylene glycol are soluble in water and miscible in all 
proportions with other polyethylene glycols (after melting, if necessary). Aqueous 
solutions of higher molecular- weight grades may form gels. Liquid polyethylene 
glycols are soluble in acetone, alcohols, benzene, glycerine and glycols. Solid 
polyethylene glycols are soluble in acetone, dichloromethane, ethanol (95%), and 
methanol; they are slightly soluble in aliphatic hydrocarbons and ether, but insoluble 
in fats, fixed oils, and mineral oil. 
8. Stability and Storage Conditions 
                 Polyethylene glycols are chemically stable in air and in solution, although 
grades with a molecular weight less than 2000 are hygroscopic. Polyethylene glycols 
do not support microbial growth, and they do not become rancid. Polyethylene 
glycols should be stored in well-closed containers in a cool, dry place. Stainless 
steel, aluminum, glass, or lined steel containers are preferred for the storage of liquid 
grades. 
9. Incompatibilities 
 The chemical reactivity of polyethylene glycols is mainly confined to 
the two terminal hydroxyl groups, which can be either esterifies or etherified. 
However, all grades can exhibit some oxidizing activity owing to the 
presence of peroxide impurities and secondary products formed by 
autoxidation. 
 Liquid and solid polyethylene glycol grades may be incompatible 
with some colouring agents. 
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Poly Vinyl Alcohol 
 
1. Nonproprietary Names 
Ph Eur: Poly (Vinyl Alcohol); USP: Polyvinyl Alcohol 
2. Synonyms 
Airvol; Alcotex; Celvol; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol; poly(alcohol 
vinylicus); Polyvinol; PVA; vinyl alcohol polymer. 
3. Empirical Formula and Molecular Weight 
             (C2H4O)n 20,000–200,000, polyvinyl alcohol is a water-soluble synthetic 
polymer represented by the formula (C2H4O)n. The value of n for commercially 
available materials lies between 500 and 5000, equivalent to a molecular weight 
range of approximately 20,000–200,000. 
4. Functional Category 
Coating agent; lubricant; stabilizing agent; viscosity-increasing agent. 
5. Applications 
Polyvinyl alcohol is used primarily in topical pharmaceutical and ophthalmic 
formulations. 
  It is used as a stabilizing agent for emulsions (0.25–3.0% w/v). 
Polyvinyl alcohol is also used as a viscosity-increasing agent for viscous 
formulations such as ophthalmic products. 
  It is used in artificial tears and contact lens solutions for lubrication 
purposes, in sustained-release formulations for oral administration, and in 
transdermal patches.  
6. Description 
Polyvinyl alcohol occurs as an odourless, white to cream-colored granular powder. 
7. Typical Properties 
              Solubility: Soluble in water; slightly soluble in ethanol (95%); insoluble in 
organic solvents. Dissolution requires dispersion (wetting) of the solid in water at 
room temperature followed by heating the mixture to about 908 
0
C for 
approximately 5 minutes. Mixing should be continued while the heated solution is 
cooled to room temperature. 
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8. Stability and Storage Conditions 
              Polyvinyl alcohol is stable when stored in a tightly sealed container in a 
cool, dry place. Aqueous solutions are stable in corrosion resistant sealed containers. 
Preservatives may be added to the solution if extended storage is required. Polyvinyl 
alcohol undergoes slow degradation at 1008 
0
C and rapid degradation at 2008 ºC; it 
is stable on exposure to light. 
9. Incompatibilities 
              Polyvinyl alcohol undergoes reactions typical of a compound with 
secondary hydroxyl groups, such as esterification. It decomposes in strong acids, 
and softens or dissolves in weak acids and alkalis. It is incompatible at high 
concentration with inorganic salts, especially sulphates and phosphates; precipitation 
of polyvinyl alcohol 5% w/v can be caused by phosphates. Gelling of polyvinyl 
alcohol solution may occur if borax is present 
 
Cyclodextrins 
 
1. Nonproprietary Names 
BP, USP-NF & PhEur: Alfadex betadex; Gamma Cyclodextrin 
2. Synonyms 
          β-Cyclodextrin beta-cycloamylose; beta-dextrin; betadexum; cavamax W7 
pharma; cycloheptaamylose; cycloheptaglucan; cyclomaltoheptose;  ß-cyclodextrin 
.    
3. Empirical Formula and Molecular Weight: C42H70O35, molecular weight 1135 
 4. Functional Category 
Solubilizing agent; stabilizing agent. 
5. Applications 
  Cyclodextrins are crystalline, no hygroscopic, cyclic 
oligosaccharides derived from starch. Among the most commonly used 
forms are α -, β -, γ cyclodextrin, which have respectively 6, 7, and 8 
glucose units. 
  Cyclodextrins may be used to form inclusion complexes with a 
variety of drug molecules, resulting primarily in improvements to 
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dissolution and bioavailability owing to enhanced solubility and improved 
chemical and physical stability. 
  In oral tablet formulations, β-cyclodextrin may be used in both wet-
granulation and direct-compression processes. The physical properties of b-
cyclodextrin vary depending on the manufacturer. However, β-cyclodextrin 
tends to possess poor flow properties and requires a lubricant, such as 0.1% 
w/w magnesium stearate, when it is directly compressed. 
6. Description 
             Cyclodextrins are cyclic oligosaccharides containing at least six D- (þ)-
glucopyranose units attached by a glucoside bonds. The three natural cyclodextrins, 
α , β, γ, differ in their ring size and solubility. They contain 6, 7, or 8 glucose units, 
respectively. Cyclodextrins occur as white, practically odourless, fine crystalline 
powder, having a slightly sweet taste. Some cyclodextrin derivatives occur as 
amorphous powders. 
7. Typical Properties of β-cyclodextrin 
 Compressibility 21.0–44.0%. 
 Density (bulk): 0.523 g/cm3. 
 Density (tapped): 0.754 g/cm3. 
 Melting point: 255–2658 0C; 
 Moisture content: 13.0–15.0% w/w. 
 Particle size distribution β-cyclodextrin: 7.0–45.0 mm 
 Solubility: Soluble 1 in 200 parts of propylene glycol, 1 in 50 of                       
water at 208 
0
C, 1 in 20 at 508 
0
C; practically insoluble in acetone, 
ethanol (95%), and methylene chloride. 
8. Stability and Storage Conditions 
β-Cyclodextrin and other cyclodextrins are stable in the solid state if  protected from 
high humidity. Cyclodextrins should be stored in a tightly sealed container, in a 
cool, dry place. 
9. Incompatibilities 
The activity of some antimicrobial preservatives in aqueous solution can be reduced 
in the presence of hydroxypropyl- β-cyclodextrin. β-cyclodextrin is nephrotoxic and 
should not be used in parenteral formulations; 
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Povidone 
 
1. Non-proprietary Names 
       BP: Povidone; JP: Povidone; PhEur: Povidone; USP: Povidone 
2. Synonyms 
E1201; Kollidon; Plasdone; Poly[1-(2-oxo-1-pyrrolidinyl)ethylene];Polyvidone; 
Polyvinylpyrrolidone; povidonum; Povipharm; PVP; 1-vinyl-2-pyrrolidinone 
polymer. 
3. Functional Category 
Disintegrant; dissolution enhancer; suspending agent; tablet binder 
4. Molecular weights: K 17 - 10,000; K 30 - 50,000                              
5. Applications 
 Although povidone is used in a variety of pharmaceutical 
formulations, it is primarily used in solid-dosage forms. In tableting, 
povidone solutions are used as binders in wet-granulation processes. 
 Povidone is used as a solubilizer in oral and parenteral formulations, 
and has been shown to enhance dissolution of poorly soluble drugs from 
solid-dosage forms 
 Povidone is additionally used as a suspending, stabilizing, or 
viscosity-increasing agent in a number of topical and oral suspensions and 
solutions 
6. Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, hygroscopic powder. Povidones with K-values equal to or lower than 30 
are manufactured by spray-drying and occur as spheres. Povidone K-90 and higher 
K-value povidones are manufactured by drum drying and occur as plates. 
6. Typical Properties 
          Density (bulk) 0.29–0.39 g/cm3  
          Density (tapped) 0.39–0.54 g/cm3  
          Melting point Softens at 1508 ºC. 
          Dynamic viscosity (m Pascals)- 5.5-8.5 (K 28/32) 
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          K-value Approximate molecular weight—50,000 
7. Stability and Storage Conditions 
 Povidone darkens to some extent on heating at 1508 0C, with a 
reduction in aqueous solubility. It is stable to a short cycle of heat exposure 
around 110–1308 0C; steam sterilization of an aqueous solution does not 
alter its properties. Aqueous solutions are susceptible to mold growth and 
consequently require the addition of suitable preservatives. 
 Povidone may be stored under ordinary conditions without 
undergoing decomposition or degradation. However, since the powder is 
hygroscopic, it should be stored in an airtight container in a cool, dry place. 
 
8. Incompatibilities 
Povidone is compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. It forms molecular adducts in solution with 
sulfathiazole, sodium salicylate, salicylic acid, phenobarbital, tannin, and other 
compounds. 
 
Crospovidone 
 
1. Nonproprietary Names 
BP: Crospovidone; PhEur: Crospovidone; USP-NF: Crospovidone 
2. Synonyms 
Crospovidonum; Crospopharm; crosslinked povidone; E1202; Kollidon CL; 
Kollidon CL-M; Polyplasdone XL; Polyplasdone XL-10; 
polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-pyrrolidinone homopolymer. 
3. Empirical Formula and Molecular Weight 
         (C6H9NO)n >1 000,000 The USP32–NF27 describes crospovidone as a water-
insoluble synthetic crosslinked homopolymer of N-vinyl-2-pyrrolidinone. An exact 
determination of the molecular weight has not been established because of the 
insolubility of the material. 
4. Functional Category 
Tablet disintegrant. 
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5. Applications in Pharmaceutical Formulation or Technology 
 Crospovidone is a water-insoluble tablet disintegrate and dissolution 
agent used at 2–5% concentration in tablets prepared by direct compression 
or wet- and dry-granulation methods. It rapidly exhibits high capillary 
activity and pronounced hydration capacity, with little tendency to form gels. 
Studies suggest that the particle size of crospovidone strongly influences 
disintegration of analgesic tablets. 
 Larger particles provide a faster disintegration than smaller particles. 
crospovidone can also be used as a solubility enhancer. With the technique of 
co-evaporation, crospovidone can be used to enhance the solubility of poorly 
soluble drugs.  
 The drug is adsorbed on to crospovidone in the presence of a suitable 
solvent and the solvent is then evaporated. This technique results in faster 
dissolution rate. 
6. Description 
             Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odourless or nearly odourless, hygroscopic powder. 
7. Typical Properties 
 Acidity/alkalinity pH =  5.0–8.0 (1% w/v aqueous slurry) 
 Polyplasdone XL-10  --  Density (bulk) (g/cm3)        --     0.323 
                                                                Density (tapped) (g/cm
3
)    --     0.461 
                                                                Surface area (m
2
/g)            --      1.2–1.4 
 Polyplasdone XL  --        Density (bulk) (g/cm3)        --     0.213   
                                                                 Density (tapped) (g/cm
3
)    --     0.273 
                                                                Surface area (m
2
/g)             --     0.6–0.8 
 Moisture content --         Approximately 60%. 
 Particle size distribution less than 400 mm for polyplasdone XL; less 
than 74 mm for polyplasdone XL-10. Approximately 50% greater than 50 
mm and maximum of 3% greater than 250 mm in size for kollidon CL. 
Minimum of 90% of particles are below 15 mm for kollidon CL-M. The 
average particle size for crospopharm type A is 100 mm and for 
crospopharm type B it is 30 mm. 
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 Solubility practically insoluble in water and most common organic 
solvents 
8. Stability and Storage Conditions 
Since crospovidone is hygroscopic, it should be stored in an airtight container in a 
cool, dry place. 
9. Incompatibilities 
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adducts with some materials. 
 
 
Poloxamer 
 
1. Nonproprietary Names 
BP: Poloxamers; PhEur: Poloxamers ; USP-NF: Poloxamer. 
2. Synonyms 
Lutrol; monolan; pluronic; poloxalkol; poloxamera; polyethylene– propylene glycol 
copolymer; polyoxyethylene–polyoxypropylene copolymer; supronic; synperonic. 
3. Typical poloxamer grade 
Poloxamer       Physical form           a             b             Average molecular weight 
407                           Solid                 101          56                   9840–1460 
3. Functional Category 
Dispersing agent; emulsifying agent; solubilizing agent; tablet lubricant; wetting 
agent. 
4. Applications in Pharmaceutical Formulation or Technology 
 Poloxamers are nonionic polyoxyethylene–polyoxypropylene 
copolymers used primarily in pharmaceutical formulations as emulsifying or 
solubilizing agents.  
 The polyoxyethylene segment is hydrophilic while the 
polyoxypropylene segment is hydrophobic. All of the poloxamers are 
chemically similar in composition, differing only in the relative amounts of 
propylene and ethylene oxides added during manufacture. Their physical 
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and surface-active properties vary over a wide range and a number of 
different types are commercially available. 
 Poloxamers are used as emulsifying agents in intravenous fat 
emulsions, and as solubilizing and stabilizing agents to maintain the clarity 
of elixirs and syrups. Poloxamers may also be used as wetting agents; in 
ointments, suppository bases, and gels; and as tablet binders and coatings. 
 Poloxamer 188 has also been used as an emulsifying agent for 
fluorocarbons used as artificial blood substitutes, and in the preparation of 
solid-dispersion systems. 
 More recently, poloxamers have found use in drug-delivery systems. 
Therapeutically, poloxamer 188 is administered orally as a wetting agent and 
stool lubricant in the treatment of constipation; it is usually used in 
combination with a laxative such as danthron. They may also be used 
therapeutically as wetting agents in eye-drop formulations, in the treatment 
of kidney stones, and as skin-wound cleansers. Poloxamer 338 and 407 are 
used in solutions for contact lens. 
5. Description 
             Poloxamers generally occur as white, waxy, free-flowing prilled granules, or 
as cast solids. They are practically odorless and tasteless. At room temperature, 
poloxamer 124 occurs as a colorless liquid. 
6 Typical Properties 
 Acidity/alkalinity pH = 5.0–7.4 for a 2.5% w/v aqueous solution. 
 Cloud point >1008 0C for a 1% w/v aqueous solution, and a 10% w/v         
aqueous solution of poloxamer 188. 
 Density 1.06 g/cm3 at 258 ºC. 
 Flash point 2608 0C. 
 Flowability: solid poloxamers are free flowing. 
 HLB value 0.5–30; 29 for poloxamer 188. 
 Melting point 52–578 ºC for poloxamer 407. 
 Moisture content: Poloxamers generally contain less than 0.5% w/w                                                
water and are hygroscopic only at relative humidity greater than 80%.  
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7. Stability and Storage Conditions 
Poloxamers are stable materials. Aqueous solutions are stable in the presence of 
acids, alkalis, and metal ions. However, aqueous solutions support mould growth. 
The bulk material should be stored in a well-closed container in a cool, dry place.  
 8. Incompatibilities 
Depending on the relative concentrations, poloxamer 188 is incompatible with 
phenols and parabens. 
 
Lactose, Spray-Dried 
 
1. Synonyms 
FlowLac 90; FlowLac 100; Lacto press Spray-Dried; Lacto press Spray-Dried 250; 
NF Lactose–315; NF Lactose–316 Fast Flo; SuperTab 11SD; SuperTab 14SD. 
2. Empirical Formula and Molecular Weight 
C12H22O11-342.30 (for amorphous); C12H22O11 H2O-360.31 (for monohydrate) 
3. Functional Category 
Directly compressible tablet excipient; tablet and capsule diluent; tablet and capsule  
filler. 
4. Applications in Pharmaceutical Formulation or Technology 
Spray-dried lactose is widely used as a binder, filler-binder, and flow aid in direct 
compression tableting. 
5. Description 
Lactose occurs as white to off-white crystalline particles or powder. It is odourless 
and slightly sweet-tasting. Spray-dried direct compression grades of lactose are 
generally composed of 80–90% specially prepared pure a-lactose monohydrate 
along with 10–20% of amorphous lactose. 
6. Typical Properties 
Super tab 11SD -- Density (bulk) (g/cm
3
)     -- 0.60. 
                              Density (tapped) (g/cm
3
) -- 0.71 
7. Stability and Storage Conditions 
Spray-dried lactose should be stored in a well-closed container in a cool, dry place. 
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8. Incompatibilities 
Lactose is a reducing sugar. The amorphous lactose, which is the most reactive form 
of lactose present in spray-dried lactose, will interact more readily than conventional 
crystalline grades) Typical reactions include the millard reaction with either primary 
or secondary amines. 
 
Lactose, Anhydrous 
 
1. Synonyms 
Anhydrous 60M; Anhydrous Direct Tableting (DT); Anhydrous DT High Velocity; 
Anhydrous Impalpable; Lactopress Anhydrous; Lactopress Anhydrous 250; 
lactosum anhydricum; lattosio; milk sugar; SuperTab 21AN; SuperTab 22AN; 
saccharum lactis. 
2. Empirical Formula and Molecular Weight 
C12H22O11- 342.30 
3. Functional Category 
Directly compressible tablet excipient; dry powder inhaler carrier; lyophilization aid; 
tablet and capsule diluent; tablet and capsule filler. 
4. Applications in Pharmaceutical Formulation or Technology 
 Anhydrous lactose is widely used in direct compression tableting 
applications, and as a tablet and capsule filler and binder. 
 Anhydrous lactose can be used with moisture-sensitive drugs due to 
its low moisture content. It may also be used in intravenous injections. 
5. Description 
Anhydrous lactose occurs as white to off-white crystalline particles or powder. 
Several different brands of anhydrous lactose are commercially available which 
contain anhydrous b-lactose and anhydrous a-lactose. Anhydrous lactose typically 
contains 70–80% anhydrous b-lactose and 20–30% anhydrous a-lactose. 
6. Typical Properties 
 Brittle fracture index 0.0362 
 Bonding index 0.0049 (at compression pressure 177.8 MPa)(1) 
 Density (true) 1.589 g/cm3 for anhydrous b-lactose 
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 Density (bulk) 0.71 g/cm3 for Super Tab 21AN. 
 Density (tapped) 0.88 g/cm3 for Super Tab 21AN. 
7. Stability and Storage Conditions 
Mould growth may occur under humid conditions (80% RH and above). Lactose 
may develop a brown coloration on storage, the reaction being accelerated by warm, 
damp conditions; stored in a well-closed container in a cool, dry place. 
8. Incompatibilities 
Lactose anhydrous is incompatible with strong oxidizers. When mixtures containing 
a hydrophobic leukotriene antagonist and anhydrous lactose or lactose monohydrate 
were stored for six weeks at 408C and 75% RH, the mixture containing anhydrous 
Lactose showed greater moisture uptake and drug degradation. Lactose anhydrous is 
a reducing sugar with the potential to interact with primary and secondary amines 
(Millard reaction) when stored under conditions of high humidity for extended 
periods. 
 
Magnesium Stearate 
 
1. Synonyms 
Dibasic magnesium stearate; magnesium distearate; magnesia stearas; magnesium 
octadecanoate; octadecanoic acid, magnesium salt; stearic acid, magnesium salt; 
Synpro 90. 
3. Functional Category 
Tablet and capsule lubricant. 
4. Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams.  
5. Description 
Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odour of stearic acid and a characteristic 
taste. The powder is greasy to the touch and readily adheres to the skin. 
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6 .Typical Properties 
        Crystalline forms High-purity magnesium stearate has been isolated as a 
trihydrate, a dihydrate, and an anhydrate. 
        Density (bulk)     -- 0.159 g/cm3 
        Density (tapped) -- 0.286 g/cm3 
        Density (true)     -- 1.092 g/cm3 
        Flash point          -- 2508 
0
C 
        Flowability:  Poorly flowing, cohesive powder. 
        Melting range      --117–1508 0C 
7. Stability and Storage Conditions 
Magnesium stearate is stable and should be stored in a well-closed container in a 
cool, dry place. 
8. Incompatibilities 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts.
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Jha RK et al. (2011)
84 
described two simultaneous approaches to improve its 
bioavailability, complexation of raloxifene with cyclodextrin(s), and formulation of 
mucoadhesive microspheres of the complex using different proportions of carbopol 
and HPMC. Significant improvement in the solubility of raloxifene was observed, 
and it differed with the combination of excipients used, Microspheres possessed 
remarkable mucoadhesion and offered controlled drug release, lasting up to 
24 hours.  FT-IR studies evidenced no interaction among drug and excipients. 
 
Balasubramaniam Jagadish et al. (2011)
85 
 enhanced dissolution and 
bioavailability of raloxifene hydrochloride by co-grinding with different super 
disintegrants namely crospovidone (CP), croscarmellose sodium (CCS) and sodium 
starch glycolate (SSG), using a ballmill, Significant enhancement in dissolution rate 
was observed with coground mixture of raloxifene with CP (1 : 5). The extent of the 
mean plasma exposures of raloxifene was 7-fold higher in animals treated with co-
ground mixture of raloxifene, CP (1: 5) compared to animals treated with milled 
raloxifene. Co-grinding of raloxifene with CP, reduced drug crystallinity, increased 
the rate and extent of dissolution, and improved bioavailability. 
 
V. K. Rai et al. (2011)
86
 enhanced dissolution of a poorly soluble drug, 
raloxifene by hydrophilic binders like PVP, HPMC, HPC and comparison was made 
with hydrophobic binder, ethyl cellulose, dissolution behaviour of different 
formulation and pure drug was studied in different relevant media, which reveals 
significant improvement in dissolution behavior of drug was observed using 
hydrophilic binder. 
 
Rahmat Talukder et al. (2011)
87 
enhanced the dissolution rates of 
raloxifene HCl by solid dispersion using polyethylene glycols (PEG). Higher the 
PEG level in dispersions, higher is the drug release rates. Mechanistically it appears 
that PEG molecules form conjugates with raloxifene through hydrogen bonding, 
which increases the dissolution rates of raloxifene. Additionally solvent method 
promotes the formation of metastable form of the drug in the dispersion, which 
further enhances the dissolution rates. 
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N. L. Prasanthi et al. (2011)
88
 fast dissolving tablets were direct compressed  
by incorporating super disintegrants like crosscarmellose sodium and sodium starch 
glycolate. The study was performed by incorporating the super disintegrants in 2 % 
and 4 % concentration for each and 2 % - 2 % in combination of both super 
disintegrants. The tablets containing super disintegrants in combination showed 
excellent in vitro dispersion time and drug release as compared to other 
formulations. 
 
M.D.Dhanaraju et al. (2011)
89
 prepared solid dispersions by hot melt 
method by employing 6 different carriers and mixing ratios (1:1, 1:2, and 1:3). 10 
batches of raloxifene formulation were conducted to select prototype formula, batch 
containing polaxomer and glycerol was selected as optimized formulation. The 
formulation obtained was investigated by preliminary stability studies. 
 
Vyas Jigar et al. (2011)
90
 prepared rofecoxib solid dispersions by different 
method using urea, PEG 6000 and PVP K30 as carriers. Solid dispersions prepared 
by fusion and solvent evaporation showing maximum solubility were selected and 
formulated into tablet. Solid dispersion prepared by fusion method using PEG 6000 
at 1:9 drug carrier ratio has shown highest improvement in the dissolution profile of 
rofecoxib. 
 
Muralidhar.S et al. (2011)
91
 formulated solid dispersions of etoricoxib 
using PEG 6000 as carrier at various proportions by using different techniques like 
physical mixtures, kneading method and solvent evaporation method. It was 
observed that solvent evaporation method exhibited higher dissolution rate than the 
corresponding solid dispersion. 
 
Bobe.K.R et al. (2011)
92
 prepared atorvastatin solid dispersion by solvent 
evaporation and fusion methods by using mannitol, PEG 4000 and PVP K30. Solid 
dispersion of drug with PEG 4000 had shown enhanced solubility with improved 
dissolution rate. The study also shows that dissolution rate of atorvastatin can be 
enhanced to considerable extent by solid dispersion technique with PEG. 
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Niranjan Kumar.M et al. (2011)
93
 prepared alprazolam solid dispersions by 
solvent evaporation method by using PEG 6000 and PVP k-30 as carriers at different 
ratios. Dissolution rates and drug releases of solid dispersions with PVP-K30 was 
most effective to enhance the dissolution rate of the drug. 
Dan Liua et al. (2006)
94
 were aimed to increase  dissolution rate of a poorly 
water-soluble drug  as solid dispersions itraconazole. Cooling curve method was 
used to determine the eutectic point of drug-poloxamer 188 mixture and the phase 
diagram of the binary system was constructed. Solid dispersions of itraconazole 
were prepared by the hot melt method and characterized by differential scanning 
calorimetry (DSC). Solubility and dissolution studies in various media were 
conducted with pure itraconazole, a physical mixture and solid dispersions. The 
eutectic mixture showed increase in drug dissolution rate. 
 
Muralidhar S et.al. (2011)
95
 formulated solid dispersions using PEG 6000 
as carrier at various proportions. The solid dispersions were prepared with different 
techniques like physical mixtures, kneading method and solvent evaporation 
method. The drug release profile was studied in water containing 2% SLS. All the 
solid dispersions exhibited superior dissolution than pure drug. Solvent evaporation 
method was found to be superior to other method. 
 
Sachin Kumar Singh et al. (2011)
96
 prepared solid dispersions by the 
solvent evaporation method at different drug: polymer ratios. The dissolution rate of 
prednisone from solid dispersions was markedly enhanced by increasing the 
polymer concentration. The tablets were prepared from solid dispersion systems 
using polyethylene glycol PEG 6000 as a carrier at low and high concentration. The 
results showed that PEG 6000-based tablets exhibited significantly higher 
prednisone dissolution (80% within 30 minutes) than did conventional tablets 
prepared without PEG 6000 (G25% within 30 minutes). 
 
Chin Sung Cho et al. (2010)
97
 developed a stabilized formulation of 
amorphous raloxifene hydrochloride, solid dispersion granules of amorphous 
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raloxifene were prepared by fluidized bed granulation with non-pareil beads, 
compressed and filmcoated to produce solid dispersion tablets. Dissolution profile of 
solid dispersion granules revealed that the  they meets the acceptance criteria, and 
the content of RXF was maintained over 95% for 5 months at accelerated conditions 
of 40
0
 C and 75% R.H. Therefore, we suggest the usefulness of SDT for the 
development of generic pharmaceuticals containing amorphous raloxifene 
. 
Dehghan M.H.G et al. (2010)
98
 prepared solid dispersions of glipizide by 
using water soluble carriers such as PEG and mannitol by fusion method and PVP K 
30 by solvent evaporation method in different ratios. It was found that the optimum 
weight ratio 1.5 for PEG-6000 shows higher solubility and dissolution rate. Finally it 
was concluded that PEG-6000 shows greater dissolution enhancing capacity than 
mannitol and PVP K 30. 
 
Arun Prasad.K et al. (2010)
99
  studied solid dispersion tablet of terbinafine 
hydrochloride by using carriers PEG 6000 (by melting method) and polyvinyl 
pyrrolidone K 30 (by solvent method) at different ratio. The solid dispersion 
showing better release profile was chosen to formulate into a tablet using 
croscaramellose sodium as super disintegrant. The solid dispersions prepared by 
solvent evaporation method using PVP K30 showed increased dissolution rate of 
terbinafine when compared to other formulations. 
 
S-H. Kim et al. (2009)
100
 characterized and Improved Dissolution Rate of 
raloxifene solid Dispersions with various ratios of PVP K-30 and poloxamer 407 in 
different concentration using spray drying technique. Their physicochemical 
characterizations were evaluated by SEM, FT-IR. The in vitro release behavior of 
solid dispersion presented at simulated gastric fluid (pH 1.2) and simulated intestinal 
fluid (pH 6.8) and the dissolution rate of hydrochloride was dramatically higher than 
commercial drug. 
 
Jani Rupal et al. (2009)
101 
used  aceclofenac, a non steroidal anti-
inflammatory drug for post traumatic pain have been prepared solid dispersions 
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using PEG-6000 and PVP at different ratios by solvent evaporation method and 
physical mixture method. It is found that PEG 6000 based solid dispersions were 
more effective in enhancing the dissolution rate of aceclofenac . 
 
Bhole P et al. (2009)
102
 studied the solid dispersion of felodipine was 
prepared by using PEG 6000 and PVA as a carrier with different drug polymer ratios 
using different techniques (physical mixing and solvent evaporation). Solid 
dispersions with both polymers increased drug release, particularly greater in the 
case of PVA than PEG 6000. 
 
Michael F et al. (2008)
103
 evaluated the pharmacokinetics of raloxifene in 
oral and intravenous formulations with HBenBCD in male Wistar–Hannover rats. 
analytical methodology to measure raloxifene and its metaboliteswas developed by 
measuring raloxifene metabolism in vitro. Formulation with HBenBCD significantly 
increased raloxifene oral bioavailability these studies demonstrate that raloxifene 
formulations containing HBenBCD significantly increased the oral bioavailability in 
rats relative to formulations that did not contain HBenBCD. 
 
Van den Mooter et al. (2006)
104
 increased the dissolution of temazepam by 
solid dispersions using PEG 6000 and PVP K30. Dispersions with PEG 6000 were 
prepared by fusion-cooling and co-evaporation, while dispersions containing PVP 
K30 were prepared by co-evaporation. In contrast to the very slow dissolution rate 
of pure temazepam, the dispersion of the drug in the polymers considerably 
enhanced the dissolution rate. The aqueous solubility of temazepam was favored by 
the presence of PEG 6000. 
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 The enhancement of oral bioavailability of poorly water soluble drugs 
remains one of the most challenging aspects of drug development. The most 
commonly used techniques to increase dissolution rate are particle size reduction, 
salt formation and lyophilization, but all these methods have practical limitations  
like  improper enhancement of solubility and all the drugs are not suitable for these 
techniques. 
To overcome all these, solid dispersion technique by solvent evaporation 
approach is successfully applied to improve the solubility and dissolution rate, there 
by bioavailability. 
The aim of this present investigation is to enhance solubility of raloxifene 
hydrochloride by formulating as solid dispersions. 
To effectuate this formulation, solubility trials are performed with different 
carriers to enhance the solubility, dissolution rate and consequently bioavailability of 
the drug. Carriers like polyethylene glycol, polyvinyl pyrrolidine, polyvinyl alcohol, 
polaxamer, polyplasdone, sugars, cellulose polymers and cyclodextrins. Further 
various molecular weight grades of these polymers are used to prepare the solid 
dispersion. 
  
The main objectives of this study are as follows: 
 To prepare the solid dispersion of raloxifene hydrochloride using different 
carriers by solvent evaporation technique. 
 To analyse the drug and carrier interactions by FTIR study. 
 To evaluate the solubility and invitro drug release of solid dispersions. 
 To prepare the immediate release tablets. 
 To evaluate the drug release from the tablets prepared with solid dispersion 
by invitro dissolution studies. 
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6.1 Materials 
 
Table 3: List of Ingredients and Suppliers 
S. No. Ingredients Manufacturer / Supplier 
1 API 
Orchid Health Care   
Pharmaceuticals 
2 Cyclodextrin Roquette Pharma 
3 PVP K17 ISP Pharmaceuticals 
4 PVP K30 ISP Pharmaceuticals 
5 Crospovidone XL ISP Pharmaceuticals 
6 Crospovidone XL 10 ISP Pharmaceuticals 
7 Polaxomer 407 Sigma Aldrich 
8 Poly Vinyl Alcohol 4-88 Merck Chemicals 
9 Poly Ethylene Glycol 6000 Sigma Aldrich 
10 Hydroxy Propyl Cellulose Shin-etsu 
11 Hydroxy Propyl Methyl Cellulose Shin-etsu 
12 Lactose monohydrate NF DMV Int. 
13 Lactose anhydrous NF DMV Int. 
14 Lactose monohydrate 200M DMV Int. 
15 Mannitol Roquette Pharma 
16 Magnesium Stearate Mallinckrodt 
17 Opadry White Colorcon 
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Table 4: List of equipments 
 
 
6.2 Methods  
 
6.2.1 Pharmaceutical buffer preparations 
6.2.1.1 0.1 N Hydrochloric acid - 0.85 ml of concentrated hydrochloric acid was 
dissolved in 100 ml of distilled water. 
6.2.1.2 Glycine buffer pH 3.0 - 25 ml 0.2 M glycine and 5.7 ml HCl were diluted to 
100 ml with distilled water. 
6.2.1.3 Acetate buffer pH 4.5 - Dissolve 2.99 gm of sodium acetate and 1.66 ml of 
glacial acetic acid in water, dilute to 1000 ml and mix, pH adjusted with glacial 
        S.NO               EQUIPMENT                     MAKE 
1.  Electronic Balance Mettler Tolido & Sartorius 
2.  Mechanical sifter Sams Techno Mumbai 
3.  Optical microscopy KAY Enterprises 
4.  Double Cone Blender Sams Techno Mumbai 
5.  Compression Machine Cadmach(16 Stations), Ahmadabad 
6.  Tap Density Tester Electrolab, Mumbai 
7.  Disintegration Tester Electrolab, Mumbai 
8.  Hardness, Thickness Tester Erweka & Varian, Mumbai 
9.  Friabilator Electrolab, Mumbai 
10.  Mechanical Stirrer Remi Motors 
11.  Conventional Coating Pan Sams Techno, Mumbai 
12.  Dissolution Apparatus USP XXIV Labindia, Disso2000 
13.  HPLC Shimadzu 
14.  UV spectroscopy Shimadzu 
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acetic acid or sodium hydroxide to 4.5. 
6.2.1.4 Phosphate buffer pH 6.8 - 100 ml of 0.1 M potassium dihydrogen 
phosphate and 44.8 ml of 0.1 M sodium hydroxide were diluted to 200 ml with 
distilled water. 
6.2.1.5 Phosphate buffer pH 7.2 - 100 ml of 0.1 M potassium dihydrogen 
phosphate and 69.4 ml of 0.1 M sodium hydroxide, dilute to 200 ml with water. 
 6.2.1.6 pH 2.5 buffer - 16.8 ml of dibutylamine in 70 ml of water. pH is  adjusted 
to 2.5 with phosphoric acid, dilute to 100 ml with purified water. 
 
6.2.2 Solubility Studies 
 500 mg of Raloxifene hydrochloride (RLX) was weighed and transferred 
into different conical flask. 50 ml of different dissolution media were transferred 
into individual conical flask and were closed appropriately. All the flasks were 
sonicated for 1 hr and the samples were filtered by using 0.45 µ PTFE filter. The 
clear solution obtained by filtration was suitably diluted with appropriate dissolution 
media and the absorbance values were noted at 280 nm by HPLC. Solubility of RLX 
in different dissolution media and results are mentioned in table 9. 
 
6.2.3 Preformulation Studies 
The drug and carrier were mixed in 1:1 ratios as per procedure 6.2.5 and 
interaction studies were evaluated by physical appearance, drug content and by 
FTIR.  
 
6.2.4 Calibration Curve of RLX 
 
6.2.4.1 Preparation of RLX Stock Solution:     
 100 mg of RLX was weighed and dissolved in 100 ml of methanol. 
6.2.4.2 Preparation of RLX Standard Dilutions: 
Aliquots of RLX stock solution was transferred into 5 volumetric flasks and 
were further diluted with Purified water so as to get 2,4,6,8, & 10 ppm of standard 
dilutions of RLX. The absorbance of the above dilutions was measured at 285 nm 
using purified water as blank in UV spectroscopy. 
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6.2.5 Preparation of RLX Solid Dispersions 
Solvent Evaporation Method 
2 gm of RLX was taken in a china dish and was dissolved in 5 ml of 
methanol. To the methanol solution, 2 gm of carrier was added and the mixture was 
evaporated at room temperature for 24 hrs. Then the mixture was collected and 
packed in an amber colored glass containers and was hermetically sealed, stored at 
ambient conditions. Compositions of various solid dispersions of RLX are given in 
table 5. 
 
Table 5: Composition of Various Solid Dispersions of RLX 
 
S. No Composition Ratio 
1 RLX + PEG-6000 1 : 1 
2 RLX + PVA 4-88 1 : 1 
3 RLX + ß-cyclodextrin  1 : 1 
4 RLX + PVP K17 1 : 1 
5 RLX + PVP K30 1 : 1 
6 RLX +  Polyplasone XL10 1 : 1 
7 RLX + Polaxomer 407 1 : 1 
8 RLX + HPC L.S 1 : 1 
9 RLX + HPMC K4MCR 1 : 1 
10 RLX + Pharmatose 200M 1 : 1 
11 RLX + Supertab 11SD 1 : 1 
12 RLX + Supertab 21AN 1 : 1 
13 RLX + Mannitol 1 : 1 
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6.2.6 Evaluation of Solid Dispersions 
 
6.2.6.1 Angle of repose:
 105  
 The frictional force in a loose powder can be measured by the angle of 
repose (θ). It is defined as, the maximum angle possible between the surface of the 
pile of the powder and the horizontal plane. If more powder is added to the pile, it 
slides down the sides of the pile until the mutual friction of the particles producing a 
surface angle θ, is in equilibrium with the gravitational force.  
 The fixed funnel method was employed to measure the angle of repose. A 
funnel was secured with its tip at a given height (h), above a graph paper that is 
placed on a flat horizontal surface. The blend was carefully pored through the funnel 
until the apex of the conical pile just touches the tip of the funnel. The radius (r) of 
the base of the conical pile was measured. The angle of repose (θ) was calculated 
using the following formula: 
             tan θ = h/r  
Where;     θ = Angle of repose  
                 h = Height of the cone  
                 r = Radius of the cone base  
 
6.2.6.2 Compressibility index
106
  
The compressibility index has been proposed as an indirect measure of bulk 
density, size and shape, surface area, moisture content, and cohesiveness of 
materials, because all of these can influence the observed compressibility index. It is 
determined by measuring both the bulk volume and tapped volume of a powder. 
Basic methods for the determination of compressibility index: There are some 
variations in the method of determining the compressibility index, the basic 
procedure is to measure the unsettled apparent volume (VO), and the final tapped 
volume (Vf), of the powder after tapping the material until no further volume 
changes occur.  
The compressibility index is calculated as follows:  
 Compressibility index = 100 × V0-Vf / V0  
Alternatively, the compressibility index may be calculated using measured values of 
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bulk density and tapped density as follows:  
Compressibility index = 100 × tapped density / bulk density  
In a variation of these methods, the rate of consolidation is sometimes measured 
rather than, or in addition to, the change in volume that occurs on tapping.  
Flow properties and corresponding angle of repose, compressibility index are shown 
in table 6.  
Table 6: Flow properties determination 
 
S. No Flow properties Angle of 
repose(θ) 
Compressibility 
Index (%) 
1 Excellent 25-30 <10 
2 Good 31-35 11-15 
3 Fair 36-40 16-20 
4 Passable 41-45 21-25 
5 Poor 46-55 26-31 
6 Very poor 56-65 32-37 
7 Very very poor > 66 >38 
 
 
6.2.6.3 Particle Size Determination 
The average particle sizes of the prepared solid dispersions were analyzed by 
optical microscopy.  
 
6.2.6.4 Determination of Drug Content of Solid Dispersions 
 Preparation of mobile phase for HPLC 
 pH 2.5 buffer and acetonitrile was mixed in the ratio 67:33 (v/v) 
respectively. 
 It was filtered through 0.45 µm membrane filter and degassed. 
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Preparation of diluents for HPLC 
pH 2.5 and acetonitrile was mixed in ratio 40 : 60 (v/v) respectively. 
 
Weigh 360 mg of solid dispersion and transferred into a 250 ml volumetric 
flask and diluents were added and kept in sonicator for about 30 minutes with 
intermediate shaking. 
A portion of the above solution was centrifuged at 2500 rpm for 10 minutes 
by using centrifuge tubes with caps. 
 5 ml of above supernatant solution was pipette into a 50 ml volumetric flask; 
volume was diluted with diluents and mixed. 
 2 ml was filtered through 0.45 µm PTFE filter. 
Chromatographic Parameters 
 The liquid chromatography is equipped with a 280 nm UV detector. 
 Column: 150 mm × 4.6 mm column that contains 5 µm packing of octyl 
silane chemically bonded to porous silica.  
 Column temperature    : 35 ºC  
 Flow rate                        :  1.5 mL/min 
 Injection volume          :  10 µL 
 Run time                        :  8 minutes 
System Suitability 
 10 µL portions of blank (diluents) & standard solution (five replicate 
injections) were injected into chromatography, chromatograms were 
recorded and responses of the major peak were measured. 
 The USP tailing factor for RLX peak should be not more than 2. 
 The USP plate count for RLX peak should be not less than 2000. 
 The %RSD for the area of RLX peak obtained from the five injections of 
standard solution should be not more than 2.0. 
 
6.2.6.5 Saturated Solubility studies 
 Saturated solubility studies of RLX solid dispersions were performed in 
purified water.  Excess amount of 500 mg RLX dispersions were weighed and 
transferred into different conical flask. 50 ml of purified water transferred into 
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individual volumetric flask and were closed appropriately. All the flasks were placed 
in the sonicator and sonicated for 1 hr. Then the flasks were removed and the 
samples were filtered by using 0.45 µ PTFE filter. The clear solution obtained by 
filtration was suitably diluted with diluents and the absorbance values were noted at 
280 nm by using purified water as blank. 
 
6.2.6.6 Dissolution Studies 
Dissolution studies of solubility enhanced dispersions were performed in a 
calibrated 8 station dissolution test apparatus equipped with paddles (USP apparatus 
II method) employing 1000 ml of purified water as a medium. The paddles were 
operated at 50 rpm and temperature was maintained at 37  ±  0.5 ºC throughout the 
experiment. 5 ml samples were withdrawn at 10, 20, 30 & 45 min of time periods as 
given by FDA dissolution data base. Equal volume of dissolution medium was 
replaced to maintain the constant volume throughout the experiment. Samples 
withdrawn and diluted with same medium and the amount of the drug dissolved was 
estimated  UV spectrophotometer at 285 nm. Dissolution profiles of solid 
dispersions are shown in table 14 and fig. 16. 
 
6.2.7 Preparation of Tablets  
Based upon the solubility studies performed, seven solubility enhanced 
dispersions were selected for further preparation as tablets. The tablets were 
prepared by direct compression process. The ratio of drug and disintegrant were 
maintained constant while the diluents concentration was adjusted according to 
assay. The compositions of various tablet formulations are given in table 7. 
The materials were individually weighed, passed through sieve #40 and 
blended for 15 minutes by using double cone blender. The powder mixture was then 
lubricated with magnesium stearate and blended for 5 min. Blend was compressed as 
tablets using cadmach 16 stations mini press. To minimize the processing variables 
all batches of tablets were compressed, under identical condition. The powder blends 
were evaluated for flow properties such as angle of repose and compressibility 
index. 
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The compressed tablets were further evaluated for their physical parameters 
such as weight uniformity, hardness, friability, disintegration time and drug content 
and the values are shown in table 15. 
 
Table 7:   Composition of RLX Solid Dispersion tablets 
 
 Corrected according to assay value 
       
6.2.8 Evaluation of tablets 
  
6.2.8.1 Weight Uniformity 
20 tablets from each batch at random were taken and weighted. The average 
weight was calculated, then each tablet was weighed individually and weights of 
each tablet were noted. The weights of individual tablets were then compared with 
the average weight. The deviation if any in the weight of individual tablets from the 
average weight was checked. This test highly describes that all tablets of a particular 
batch should be uniform in weight. If any weight variation is there, that should be 
within the I.P limits. The test was considered correct if not more than two tablets fall 
outside the I.P limits out of twenty tablets taken for the test
124
. 
 
 
 
 
Ingredient (mg/tablet) 
Formulations 
RLX1 RLX2 RLX3 RLX4 RLX5 RLX6 RLX7 
Solid dispersions*
 
120.4 113.6 121.5 129.1 127.7 123.4 120.9 
Supertab DCL 21 AN*
 
83.0 80.0 82.0 74.0 76.0 80.0 83.0 
Supertab DCL 11 SD 20.88 20.88 20.88 20.88 20.88 20.88 20.88 
Polyplasdone XL 14.4 14.4 14.4 14.4 14.4 14.4 14.4 
Magnesium stearate 1.2 1.2 1.2 1.2 1.2 1.2 1.2 
Opadry white 7.2 7.2 7.2 7.2 7.2 7.2 7.2 
weight of tablet  (mg) 247.2 247.2 247.2 247.2 247.2 247.2 247.2 
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 Table 8: Limits for the Average Weight of Tablets 
Average Weight Percentage Deviation 
80 mg or less 10 
More than 80mg but less than 250mg 7.5 
250 mg or more 5 
 
6.2.8.2 Hardness    
Hardness of the tablets was determined by using erweka hardness tester. The 
tablet to be tested is placed on the surface of the hardness tester and the reading were 
noted from the display which indicates the pressure required in kp to break the 
tablet. The hardness of tablet depends on the weight of the material used, space 
between the upper and lower punches at the time of compression and pressure 
applied during compression. 
6.2.8.3 Friability 
Friability test was performed by using friabilator. 6.5 mg of tablets from each 
batch were weighed and placed in a friabilator chamber and it was allowed to rotate 
for 100 revolutions. During each revolution these tablets fall from a distance of six 
inches to undergo shock. After completion of 100 revolutions, tablets were again 
weighed and the loss in weight indicated friability. The acceptance limits of weight 
loss should not be more than 1%. This test was performed to evaluate the ability of 
the tablets to withstand abrasion in packing, handling and transporting.  
6.2.8.4 Disintegration Time 
Six tablets were placed in six tubes of basket and 800 ml of water is taken, 
maintained at 37 ± 2 
0
C. Time was noted for all the tablets to disintegrate 
completely. 
6.2.8.5 Estimation of Drug Content  
20 tablets were crushed and the weight equivalent to 180 mg of RLX were 
transferred into a 250 ml volumetric flask and diluents were added and kept in 
sonicator for about 30 minutes with intermediate shaking. A portion of the above 
solution was centrifuged at 2500 rpm for 10 minutes by using centrifuge tubes with 
caps. 5 ml of above supernatant solution was pipette into a 50 ml volumetric flask, 
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volume was diluted with diluents and mixed. 2 ml was filtered through 0.45 µm 
PTFE filter and injected in HPLC. 
 
 6.2.8.6 Dissolution Studies 
Dissolution studies of solubility enhanced dispersions were performed in a 
calibrated 8 station dissolution test apparatus equipped with paddles (USP apparatus 
II method) employing 1000 ml of purified water as a medium. The paddles were 
operated at 50 rpm and temperature was maintained at 37 ºC ± 1 ºC throughout the 
experiment. 5 ml samples were withdrawn at 10, 20, 30 & 45 min of time periods as 
given by FDA dissolution data base. Equal volume of dissolution medium was 
replaced to maintain the constant volume throughout the experiment. Samples 
withdrawn and diluted with same medium and the amount of the drug dissolved was 
estimated U.V spectrophotometer at 285 nm. Dissolution profiles of solid dispersion 
tablets were shown in table 16 and fig. 17. 
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Table 9: Solubility Studies of RLX in Different Dissolution Media 
 
S.NO Dissolution Media Amount of Drug 
Soluble (mg/ml) 
1 Purified water 0.44 
2 0.1 N Hydrochloride 0.24 
3 0.1% Polysorbate 0.61 
4 pH 3.0 Glycine buffer 0.12 
5 pH 4.5 acetate buffer 0.19 
6 pH 6.8 phosphate buffer 0.18 
7 pH 7.2 phosphate buffer 0.32 
 
Table 10:  Calibration curve for the estimation of RLX in purified water. 
 
S.NO Concentration (µg/ml) Absorbance 
1 0 0 
2 2 0.108 
3 4 0.225 
4 6 0.345 
5 8 0.466 
6 10 0.608 
 
Fig 7: Calibration curve for the estimation of RLX in purified water 
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 Table 11: Preformulation Studies on RLX 
 
S. 
No 
 
Description 
Method Evaluated 
Physical Assay 
0 Day 1 Month 0 Day 1 Month 
1 RLX Dark yellow Complied Complied Complied 
2 RLX + 
PEG-6000 
Light yellow Complied Complied Complied 
3 RLX + 
PVA 4-88 
Light yellow Complied Complied Complied 
4 RLX + ß-
cyclodextrin  std 
Light yellow Complied Complied Complied 
5 RLX + PVA    K 17 Intense 
yellow 
Complied Complied Complied 
6 RLX + PVP K30 Intense 
yellow 
Complied Complied Complied 
7 RLX + 
Polyplasdone Xl 10 
Intense 
yellow 
Complied Complied Complied 
8 RLX + Polaxomer 
408 
Light yellow Complied Complied Complied 
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Table 12:   Flow Properties and Drug Content of RLX Solid Dispersions 
S.NO 
Solid 
Dispersions 
Angle of 
Repose 
Carr’s 
Index 
(%) 
Particle 
Size 
(microns) 
Drug 
Content 
(%) 
1 RLX 1 20 14 82±4.1 94±0.21 
2 RLX 2 32 18 102±7.6 97±0.34 
3 RLX3 30 18 87±6.9 97±0.31 
4 RLX4 23 16 72±6.5 99±0.23 
5 RLX5 22 15 75±2.9 93±0.37 
6 RLX6 24 16 97±6.5 99±0.28 
7 RLX7 26 14 92±2.8 105±0.33 
 All values are expressed as mean ± SD, n=3 
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Fig. 8: FTIR spectra of RLX 
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Fig. 9: FTIR spectra of  RLX-PEG 6000 
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Fig. 10: FTIR spectra of  RLX-PVA 4-88 
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Fig. 11: FTIR spectra of  RLX-ß CD 
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Fig. 12: FTIR spectra of  RLX-K 17 
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Fig. 13: FTIR spectra of  RLX-K 30 
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      Fig. 14: FTIR spectra of RLX-POLY XL 10 
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Fig. 15: FTIR spectra of  RLX-POLAXOMER 407 
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Table 13: Composition of Various Solid Dispersions of RLX 
S.NO Composition Ratio Amount of Drug 
Soluble (mg/ml) 
 1 RLX + PEG- 6000 RLX 1 1 : 1 0.64 
2 RLX + PVA 4-88 RLX 2 1 : 1 0.90 
3 RLX + ß-cyclodextrin  RLX 3 1 : 1 2.18 
4 RLX + PVP K 17 RLX 4 1 : 1 1.97 
5 RLX + PVP K 30 RLX 5 1 : 1 1.48 
6 RLX +  Polyplasone XL 10 RLX6 1 : 1 1.19 
7 RLX + Polaxomer 407 RLX 7 1 : 1 1.07 
8 RLX + HPC L.S RLX 8 1 : 1 0.41 
9 RLX + HPMC K4 MCR RLX9 1 : 1 0.46 
10 RLX + Pharmatose 200 M RLX 10 1 : 1 0.48 
11 RLX + Supertab 11SD RLX11 1 : 1 0.48 
12 RLX + Supertab 21AN RLX12 1 : 1 0.49 
13 RLX + Mannitol RLX13 1 : 1 0.47 
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Table 14: Drug Release Profile of RLX Solid Dispersions  
All values are expressed as mean ± SD, n=3 
 
 
 
 
 
 
 
 
 
 
Time 
(min) 
Cumulative % drug release 
RLX RLX1 RLX2 RLX3 RLX4 RLX5 RLX6 RLX7 
10 2±1.8 8±4.1 18±1.5 5±2.2 9±2.8 6±2.1 6±2.4 20±4.1 
20 7±2.1 20±1.7 76±0.9 16±1.6 25±1.7 20±2.2 28±1.8 52±4.1 
30 12±1.7 22±1.8 87±0.8 29±1.7 41±2.6 25±2.4 41±2.1. 54±4.1 
45 19±0.6 29±2.1 95±4.1 70±1.6 43±1.4 32±1.3 53±2.5 62±4.1 
Infinity 32±1.9 40±1.1 96±1.7 100±2.4 65±0.8 36±2.1 55±1.6 78±4.1 
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Fig. 16: Dissolution Profiles of RLX Tablet Formulations Using Solid Dispersions 
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Table.15:  Evaluation of RLX Tablet Formulations 
All values are expressed as mean ± SD, n=10 
 
 
 
 
 
Tablet 
Weight 
uniformity 
(mg/tablet) 
Thickness 
(mm) 
Hardness 
(kg/cm
2
) 
Friability 
(%) 
D.T 
(min) 
Drug 
content 
(%) 
RLX1 241±0.62 4.2±0.21 6.0±0.46 0.21 5-6 101.1 
RLX 2 240±0.92 4.2±0.16 5.0±0.39 0.23 2-3 99.4 
RLX3 241±0.61 4.2±0.11 
9.0±0.53 0.46 2-3 98.6 
RLX4 240±0.51 4.6±0.12 6.0±0.85 0.15 3-4 102.3 
RLX5 240±0.71 3.0±0.12 5.0±0.86 0.20 8-9 101.4 
RLX6 240±0.62 4.4±0.11 10.0±0.24 0.79 1-2 102.1 
RLX7 238±0.91 4.5±0.12 
3.0±0.43 0.17 9-10 103.4 
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Table 16: Drug Release Profiles of RLX Tablet Formulations Prepared by Solid 
dispersion technique. 
All values are expressed as mean ± SD, n=3 
 
 
 
 
 
Time 
(min) 
Cumulative % drug release 
RLX1 RLX2 RLX3 RLX4 RLX5 RLX6 RLX7 
10 3±2.2 10±1.7 14±0.5 5±0.3 9±1.5 12±2.3 12±1.6 
20 18±2.4 25±0.5 35±0.9 27±1.6 17±2.5 25±1.6 44±1.8 
30 23±2.6 34±1.6 63±2.3 36±0.6 28±2.0 32±1.5 64±0.7 
45 35±0.6 46±1.1 74±1.2 47±1.8 40±2.5 46±1.5 89±0.7 
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Fig. 17: Dissolution Profiles of RLX Tablet Formulations Using Solid Dispersions 
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Solubility studies were performed in wide range of pH, it is observed that 
RLX shows very poor solubility. 
Preformulation studies  were carried with 1:1 ratios of RLX and carriers  for  1 
month and evaluated for physical appearance showed no change in colour and assay 
values are satisfactory. FTIR of RLX showed its characteristic peaks at 3530 due to 
phenol -OH group, 1641 due to C=O stretching, 1595 due to C=C stretching, , 806 
due to thiophene C-H, and 1158 due to C-O stretching. FTIR spectras of RLX and 
carriers showed that there was no significant change in the absorption spectrum. 
This indicates that there was no drug and carriers incompatibility. 
Saturated solubility studies of solid dispersions in the purified water were 
performed which showed ß-cyclodextrin and polaxomer has maximum solubility, of 
all the carriers used seven were found to be satisfactory.  
ß-cyclodextrin being hydrophilic in nature it undergoes complexation with 
hydrophobic drugs. Inclusion complexes are formed by the insertion of the nonpolar 
molecule or the nonpolar region of one molecule (known as guest) into the cavity of 
another molecule or group of molecules (known as host). The forces driving 
complexation were attributed to (i) the exclusion of high energy water from the 
cavity, (ii) Vander walls interactions, and (iii) hydrogen and hydrophobic bindings. 
Polaxomer being a surfactant, when dispersion comes in contact with water, the 
polymer particles might have hydrated rapidly into the polymer solution, 
solubilizing the adjacent drug particles and subsequently releasing the drug into the 
medium.  
Flow properties: All the solid dispersions prepared  were evaluated for angle of 
repose, Carr’s index, avg. particle size and drug content. It was found that all the 
dispersions exhibited excellent flow properties and fair compressibility index.  The 
average particle size was in the range of 72±5 - 102±4 microns. The drug content for 
all dispersions were in the range of 93 – 105 %. Thus all the solid dispersions are 
suitable for compression as immediate release tablets. 
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Dissolution studies were performed for all the solid dispersions by using USP  
apparatus II (paddle). The drug from various dispersions were released at a faster 
rate compared to pure drug . The drug release from solid dispersions were in the 
order of PVA >Polaxomer> XL10 >PVP K17> ß-cyclodextrin> PVP K30 >PEG 
6000.  
Tablets: Solid dispersions were compressed into tablets and were evaluated for 
hardness, friability, disintegration time and assay.  All the batches were found to be 
in specified limits. 
Dissolution studies were performed for all the tablet formulations. The drug 
release of tablet formulations in the presence of various carriers were in the order of 
Polaxomer > ß-cyclodextrin > PVP K17 > PVA > Polyplasdone XL10 > PVP K30 > 
PEG 6000. 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
AND 
CONCLUSION 
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The objective of this study was to prepare Raloxifene hydrochloride solid 
dispersions with an aim to improve the solubility and dissolution rate  by using 
different carriers. Raloxifene hydrochloride is a selective estrogen receptor 
modulator used as anti osteoporotic agent in post menopausal. It is available as pale 
yellow crystalline and is practically not soluble in water. Based on the 
biopharmaceutical properties RLX was selected as a drug candidate for improving 
its solubility and dissolution rate. Solid Dispersions were prepared using various 
carriers by solvent evaporation method. They were evaluated for flow properties and 
drug release studies.  
Preformulation studies were performed on RLX and carriers used in the 
formulations and they found to be compatible. Characterization was done by FTIR 
study and interpreted that they were compatible without interactions. Solid 
dispersions prepared by solvent evaporation method using different carriers at 1:1 
ratio and they showed enhanced solubility as compared to API. Carriers, ß-
cyclodextrin, polaxomer and polyplasdone showed enhanced dissolution rate.  The 
flow properties such as angle of repose and carr’s index were evaluated and found to 
be excellent flow characteristics and fair compressibility index. The direct 
compression process was found to be suitable for compressing solid dispersions as 
tablets. Evaluation of tablets was performed and they were in specified limits. Based 
on the dissolution profiles of solid dispersions and their tablets it is concluded that 
solubility of raloxifene hydrochloride is enhanced using inclusion complex (ß-
cyclodextrin), hydrophilic polymer (PVA) and surfactant (polaxomer). 
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